 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.[ADDRESS_527932]  ............... 13  
3.1 STUDY AGENT  ........................................................................................................................ 13 
3.2 PRECLINICAL PHARMACOLOGY  ............................................................................................. 13 
3.2.1  In Vitro  ............................................................................................................................ 13 
[IP_ADDRESS]  Protection from Oxygen/Glucose Deprivation ............................................. 13  
[IP_ADDRESS]  Trophic Factor Secretion ............................................................................. 14  
[IP_ADDRESS]  Extracellular Matrix Secretion ..................................................................... 15  
[IP_ADDRESS]  Epi[INVESTIGATOR_418533] ...................................................................................... 15  
[IP_ADDRESS]  Effects on Osteogenesis and Adipogenesis................................................... 17  
[IP_ADDRESS]  Anti-inflammatory and Immunosuppressive Properties ............................... 17  
3.2.2  In Vivo Stroke Models ..................................................................................................... 18 
[IP_ADDRESS]  Study N-030 .................................................................................................. 18  
[IP_ADDRESS]  Study N-034 .................................................................................................. 20  
[IP_ADDRESS]  Study N-035 .................................................................................................. 22  
3.3 MECHANISM OF ACTION  ......................................................................................................... 24 
3.4 ADME  .................................................................................................................................... 24 
3.4.1  PSP021 (N-032) .............................................................................................................. 24 
3.4.2  MPI 1295- 001 ................................................................................................................. 25 
3.4.3  N-029 .............................................................................................................................. 26 
3.4.4  N-033 .............................................................................................................................. 26 
3.5 OVERALL PRECLINICAL PHARMACOLOGY AND ADME  SUMMARY  ...................................... 27 
3.6 TOXICOLOGY  .......................................................................................................................... 31 
3.6.1  12-Month Rat Tumorigenicity  ......................................................................................... 31 
3.6.2  4-Month Rat Tumorigenicity Bridging Study .................................................................. 31 
3.6.3  CsA Dose Selection for Monkey Safety Study  ................................................................. 32 
3.6.4  Study Number MPI -004; MPI [INVESTIGATOR_133720]  ......................................................................... 32 
3.6.5  One-Month Cynomolgus Monkey +- CsA ........................................................................ 32 
3.6.6  6-Month Toxicity: Cynomolgus monkey ......................................................................... 32 
3.7 SUMMARY OF PRECLINICAL SAFETY STUDIES  ....................................................................... 33 
3.8 SUMMARY OF KNOWN AND POTENTIAL RISKS AND BENEFITS  ............................................. 36 
4.0 DESCRIPTION AND JUSTIFICATION OF TREATMENT REGIMEN ........... 36  
4.1 DOSAGES  ................................................................................................................................ 36 
4.2 JUSTIFICATION  ....................................................................................................................... 36 
5.0 NO CYCLOSPORINE A ........................................................................................... 36  
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 3 of 85 5.1 RATIONALE  ............................................................................................................................ 36 
5.2 MONITORING FOR HUMORAL OR CELL-MEDIATED IMMUNE RESPONSE  ............................... 37 
6.0 STUDY PARAMETERS AND OBJECTIVES  ........................................................ 37  
6.1 PARAMETERS  ......................................................................................................................... 37 
6.1.1  Safety .............................................................................................................................. 37 
6.1.2  Efficacy  ........................................................................................................................... 37 
6.2 OBJECTIVES  ............................................................................................................................ 38 
6.2.1  Primary Objective  ........................................................................................................... 38 
6.2.2  Secondary Objectives ...................................................................................................... 38 
7.0 SURGICAL AND IMPLANTATION PROCEDURES  .......................................... 38  
8.0 PATIENT SELECTION  ............................................................................................ 39  
8.1 INCLUSION CRITERIA  ............................................................................................................. 39 
8.2 EXCLUSION CRITERIA  ............................................................................................................ 39 
9.0 INVESTIGATIONAL PLAN  .................................................................................... 40  
9.1 OVERALL STUDY DESIGN  ...................................................................................................... 40 
9.2 DURATION OF PATIENT PARTICIPATION  ................................................................................ 41 
10.0  STUDY ASSESSMENTS  ........................................................................................ 41  
10.1  SCHEDULE OF STUDY ACTIVITIES  ...................................................................................... 41 
10.2  PRE-STUDY EVALUATION AND BASELINE (PRE-SCREEN , SCR. 1, WEEK -3 AND SCR. 2, 
 W EEK -1) ............................................................................................................................ 44 
10.2.1  Pre-Screen (Optional) .................................................................................................... 44 
10.2.2  Scr. 1, Week -3 ................................................................................................................ 44  
10.2.3  Scr. 2, Week -1 (±2 Days) ............................................................................................... 45 
10.3  BASELINE AND ENROLLMENT (DAYS -2 TO 1, NOT INCLUDING WEEKENDS ) ..................... 45 
10.3.1  Baseline (Weekday -1 to - 2 ) ........................................................................................... 45 
10.3.2  Enrollment (Days - 1 or 1)  ............................................................................................... 45 
10.4  CELL ADMINISTRATION (DAY 1) ........................................................................................ 46 
10.5  FOLLOW -UP PERIOD (STUDY DAY 2) ................................................................................. 46 
10.6  FOLLOW -UP PERIOD (STUDY DAY 8) ................................................................................. 46 
10.7  FOLLOW -UP PERIOD (END OF MONTHS 1, 2, 3, 4 ± 5 DAYS) .............................................. 47 
10.8  FOLLOW -UP PERIOD (END OF MONTH 6 ±7 DAYS) ............................................................ 47 
10.9  FOLLOW -UP PERIOD (MONTHS 9, 12 ±7 DAYS) ................................................................. [ADDRESS_527933] EVALUATION (END OF MONTH 24 ±14  DAYS OR EARLY WITHDRAWAL ) ................ 48 
11.0  DESCRIPTION OF STUDY TREATMENT........................................................ 48  
11.1  STUDY DRUG DESCRIPTION  ............................................................................................... 48 
11.2  STUDY DRUG PACKAGING .................................................................................................. 48 
11.3  STUDY DRUG SHIPMENT AND STORAGE  ............................................................................ 48 
11.4  PREPARATION AND ADMINISTRATION  ............................................................................... 49 
11.5  STUDY DRUG ACCOUNTABILITY PROCEDURES  ................................................................. 49 
12.0  CONCOMITANT MEDICATIONS  ...................................................................... 49  
13.0  STUDY WITHDRAWAL/TERMINATION ........................................................ [ADDRESS_527934]: SERUM OR URINE β-HCG..................................................................... 51 
15.5  ANTIBODIES TO HLA  ANTIGENS ON SB623 ....................................................................... 51 
15.6  SERUM ANTIBODIES TO SB623 .......................................................................................... 51 
15.7  PBMC  FUNCTION  ............................................................................................................... 51 
15.8  CLINICAL STROKE EVALUATIONS  ...................................................................................... 52 
15.8.1  European Stroke Scale (ESS) .......................................................................................... 52 
15.8.2  National Institute of Health (NIH) Stroke Scale ............................................................. 52 
15.8.3  Modified Rankin Scale (MRS) ........................................................................................ [ADDRESS_527935] .................................... 55  
18.0  STATISTICAL METHODS  ................................................................................... 55  
18.1  OVERVIEW OF ANALYSIS  ................................................................................................... 55 
18.1.1  Safety Parameters  ........................................................................................................... 55 
18.1.2  Efficacy Parameters ........................................................................................................ 56 
18.1.3  Efficacy Objectives  ......................................................................................................... 56 
18.2  PATIENTS TO BE INCLUDED IN THE ANALYSES  .................................................................. 56 
18.2.1  Efficacy Population ........................................................................................................ 56 
18.2.2  Safety Population  ............................................................................................................ 56 
18.3  ANALYSIS OF EFFICACY  ..................................................................................................... 56 
18.3.1  Primary Analysis ............................................................................................................ 56 
18.3.2  Secondary Analyses  ........................................................................................................ 56 
18.4  ANALYSIS OF SAFETY  ......................................................................................................... 57 
18.5  DETERMINATION OF SAMPLE SIZE ..................................................................................... 57 
18.6  DEVIATIONS FROM THE PROTOCOL ANALYSIS PLAN ......................................................... 57 
19.0  ADMINISTRATION OF THE STUDY ................................................................ 57  
19.1  REGULATORY CONSIDERATIONS  ........................................................................................ 57 
19.2  INDEPENDENT ETHICS COMMITTEE (EC)/I NSTITUTIONAL REVIEW BOARD (IRB)  ............ 57 
19.3  PATIENT INFORMATION AND INFORMED CONSENT  ............................................................ 58 
19.4  ADHERENCE TO THE PROTOCOL  ......................................................................................... 58 
19.5  PROTOCOL MODIFICATIONS  ............................................................................................... 59 
19.6  DATA COLLECTION  ............................................................................................................ 59 
19.7  MAINTAINING RECORDS ..................................................................................................... 60 
19.8  MONITORING , AUDITING , INSPECTING  ............................................................................... 60 
19.9  CONFIDENTIALITY  .............................................................................................................. 60 
19.10  PUBLICATION POLICY  ......................................................................................................... 61 
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 5 of 85 20.0  APPENDIX A: SAMPLE INFORMED CONSENT  ............................................ 62  
21.0  APPENDIX B:  ESSENTIAL STUDY DOCUMENTS ......................................... 70  
22.0  APPENDIX C: WHO STANDARD TOXICITY CRITERIA  ............................. 74  
23.0  APPENDIX D: COGNITIVE FUNCTION TEST BATTERY  ........................... [ADDRESS_527936] OF TABLES  
Table 1  Summary of Preclinical Pharmacology and ADME Studies  ........................................ 28 
Table 2  Summary of Preclinical Safety Studies  .......................................................................... 34 
Table 3  Dosages, Volumes and Cell Concentrations ................................................................... 36 
Table 4  Study Procedures Flow Chart  ......................................................................................... 42 
Table 5  Relationship of Adverse Event to the Administration of the Study Drug  ................... 54 
Table 6  WHO (World Health Organization) Toxicity Criteria by [CONTACT_27891] ................................ [ADDRESS_527937]: 1- Month Rat Study  ........................................................ 19 
Figure 7  Bederson Neurologic Exam : 1-Month Rat Study  ...................................................... [ADDRESS_527938]: 3- Month Rat Study  ........................................................ 20 
Figure 10  Bederson Neurologic Exam: 3 -Month Rat Study  ...................................................... 21 
Figure 11  CsA is not Needed for Long- Term Improvement of Stroke Deficits  ........................ 23 
Figure 12  Primate Needle Track  ................................................................................................... 25 
Figure 13  Primate Y -ISH Staining  ............................................................................................... 25 
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 6 of 85 1.0 PROTOCOL SYNOPSIS  
Protocol #:  SB-STR01  
Title:  A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells 
(SB623) in Patients with Stable Ischemic Stroke  
Study 
Objectives:  Primary : To evaluate the safety and tolerability of intracranial 
administration of SB623 cells.  Safety will be determined during [ADDRESS_527939]-implant.  
Secondary : To evaluate clinical and radiographic response to 3 dose levels 
of intracranial administration of SB623 cells.  The major efficacy endpoints will  be determined at 6 months; measures will also be at 1, 2, 3, 
4, 9, 12, and [ADDRESS_527940] resulted in imp rovement of neurological behavior.  
The safety of implanted SB623 cells was evaluated in a 6 -month primate 
study and in 2 nude rat studies (4 mos. and 12 mos.) .  The primates were 
immunosuppressed with cyclosporine and the nude rats further immunosuppressed with an anti -NK cell antibody.  There were no SB623-
related clinical, laboratory, or his tological abnormalities found.  
The stereotactic surgical delivery of cells to patients with stroke has been shown to have an acceptable safety profile in two prior cli nical studies with 
another product.  In addition, a retrospective study of over 2,650 patient s 
undergoing stereotactic surgery during a 28- year period at one major clinic 
has shown a high degree of safety with the procedure.  
Finally, the European Stroke Sc ale (ESS), the Modified Rankin Score, the 
National Institute of Health Stroke Scale (NIHSS), the Fugl -Meyer scale 
for motor function, and a neurocognitive battery ( e.g., Rey Complex Figure 
Test), have been used and validated , at least for acute stroke.  
Fluorodeoxyglucose positron emission tomography (FDG -PET) imaging 
has shown that changes in metabolic activity relative to baseline in the infarct area and surrounding areas correlated with performance on the 
motor subscale of the ESS.  
Study Design  This is an open -label safety study of stereotactic, intracranial injection of 
SB623 cells in patients with hemiparesis from stable ischemic stroke who have remained stable during the prior 3 weeks  (based on NIHSS 
assessments at weeks - 3 and -1).  While primarily a  safety study, efficacy 
parameters will also be evaluated.  Three cohorts will receive escalating single doses of SB623, which are to be stereotactically implanted into grey or white matter sites adjacent to the infarct region.  One burr -hole 
craniostomy w ill be created, and cells implanted using 3 needle tracks with 
5 deposits for each track at varying depths around the damaged area.  Cell 
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 7 of 85 implantation will be standardized as to volume (20 µL/deposit) and rate (10 
µL/min) , with spacing between each implant  of approximately [ADDRESS_527941]-physical therapy, and with no more than ± 1 point change in clinical 
stroke evaluation (using NIHSS ) in th e [ADDRESS_527942] shown that over 90% of ischemic stroke patients are stable by [ADDRESS_527943] -stroke.  The upper limit of 36 mos. was 
chose n to allow for the possibility of some brain tissue plasticity 
remaining , while mainly to increase the potential patient population . 
Statistical 
Considerations  Based on the animal data, no dose -limiting toxicity is expected.  However, 
if the true rate of toxicity is 40%, a sample size of 6 patients per cohort would result in a < 5% chance of missing a dose -limiting toxicity.  A 
pooled analysis of changes from Baseline for all patients for each of the efficacy parameters will be conducted.  In addition, a possible dose -
response will be evaluated.  
No. of Patients  18 Evaluable  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 8 of 85 No. of Study 
Sites  Up to 8 
Inclusion 
Criteria  • Age 18 -75 years  
• Documented history of completed ischemic stroke in subcortical region 
of MCA or lenticulostriate artery  with or without cortical involvement, 
with correlated findings preferably by [CONTACT_418566]  
• Between [ADDRESS_527944]-stroke, and having a motor neurological deficit  
• No significant further improvement with physical therapy/rehabilitation  
(confirmed by [CONTACT_418567] ±1 within  three weeks 
prior to enrollment) 
• Modified Rankin Score of 3 or 4  
• NIH Stroke score of >7 
• Two evaluations during prior 3 weeks with no more than  ±1 point 
change in clinical evaluation using the NIH Stroke  Scale  
• Able and willing to undergo computed tomography (CT), magnetic resonance imaging (MRI), and positron- emission tomography (PET) 
scans of the head  
• Agree that use of antiplatelet, anti -coagulant, or non- steroidal anti-
inflammatory drugs to be determined by  [CONTACT_418568]  2012 guideline  “Perioperative Management 
of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of 
Thrombosis, 9
th Edition: American College of Chest Physicians 
Evidence- Based Clinical Practice Guidelines”,  if applicable1, provided 
that no antiplatelet, anti-coagulant, or non- steroidal anti- inflammatory 
drugs are to be restarted post surgery until after the Day 8 MRI is read 
and are determined to be safe to re -start 
• Normal emotional status; i.e. , no disabling psychological deficits 
• Ability of patient or legal authorized representative to understand and 
sign an Informed Consent  
Exclusion 
Criteria  • History of more than 1 symptomatic stroke  
• History or presence of any other major neurological disease  
• Cerebral infarct size >100 cm3 measured by [CONTACT_9268]  
• Myocardial infarction within prior 6 mos. 
• Known presence of any malignancy except squamous or basal cell 
carcinoma of the skin  
• History of CNS malignancy 
• History of seizures or current use of antiepi[INVESTIGATOR_7377]  
• Uncontrolled systemic illness, including, but not limited to: hypertension (systolic >150 mm Hg  or diastolic >95 mm Hg ); diabetes; 
renal, hepatic, or cardiac failure  
• Uncontrolled psychiatric illness, including depression (Hamilton Score 
of >14) 
• Total bilirubin >1.5 mg/dL 
• Serum creatinine >1.5 mg/dL  
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 9 of 85 • Hemoglobin <10.0 g/dL  
• Absolute neutrophil count <2000 /mm3 
• Lymphocytes <800 /mm3 
• Platelet count <100,000/mm3 
• Liver disease supported by [CONTACT_42458] (SGOT) or ALT (SGPT) ≥2.5 x 
institutional upper limit of  normal  
• Serum calcium >11.5 mg/dl  
• International Normalized Ratio of Prothrombin Time (INR) >1.2  
• Signs and symptoms of intracranial herniation or increased intracranial pressure  
• Acute intracranial hemorrhage  
• Use of neuroleptic drugs  
• Unexplained abnormal pre operative test values (blood tests, 
electrocardiogram [ECG], chest X -ray); patients with 
electrocardiographic evidence to suggest a recent myocardial 
infarction, major dysrhythmia, x -ray evidence of infection, atrial 
fibrillation, or congestive heart failu re will be excluded  
• Participation in any other investigational trial within 4 weeks of initial 
screening and within 7 weeks of study entry  
• Botulinum toxin injection, phenol injection, intrathecal baclofen, or any 
other interventional treatments for spasticity (except bracing and splinting) within the previous 3 mos.  
• Ongoing use of herbal or other non- traditional drugs  
• Ongoing drug or alcohol abuse  
• Contraindications to head CT, MRI, or PET  
• Pregnant or lactating  
• Female patients of childbearing potentia l unwilling to use an adequate 
birth control method during the first 6 months of the study  
• Presence of serum antibodies to donor SB623 cells with a Luminex 
value of >1000 MFI (Maximum Fluorescence Intensity) : HLA Class I 
(HLA -A*23:PWMV, HLA -A*68:CGBR; HLA -B*45:FJH, HLA -
B*53:KJW; or HLA -Bw4, HLA -Bw6; HLA -Cw*04:SSWB, HLA -
Cw*16:01); or Class II (HLA -DRB1 *13:NGUB, HLA -DRB1 *16:02; 
HLA -DQB1*05:CHZY, HLA -DQB1*05:BK; HLA -DQA1*01:DVB, 
HLA -DQA1*X, HLA -DRB3,4,5: 3*03:01, HLA -DRB3,4,5: 5*02:02)  
• Any other condition or  situation that the investigator believes may 
interfere with the safety of the subject or the intent and conduct of the study  
Dosage, Mode of 
Administration, and Treatment Duration  All dosages of cells to be administered stereotactically through one burr -
hole craniostomy within and adjacent to the infarct using 3 needle tracks and 5 cell deposits per track at varying depths (20 µL each).  
Cohort 1:  2.5 X 106 SB623 Cells  (8.3 X 106 cells/mL)  
Cohort 2:  5.0 X 106 SB623 Cells  (17 X 106 cells/mL)  
Cohort 3:  10 X 106 SB623 Cells   (33 X 106 cells/mL)  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 10 of 85 Duration of 
Patient Study 
Participation  Two years (except if there is an unresolved Grade [ADDRESS_527945] 
possibly related to the therapy, in which case the patient will be followed 
until resolved or reduced t o Grade 1).  
Cell Storage 
Conditions and 
Reconstitution  SB623 cells will be kept frozen in vapor phase liquid nitrogen at study sites 
within the shippi[INVESTIGATOR_418534], then thawed, washed, and re-suspended at one of 3 different concentrati ons in Plasma -Lyte A® as 
summarized above.  
Efficacy 
Parameters  • Clinical improvement of stroke symptoms using the European Stroke 
Scale, the NIH Stroke Scale,  and the Modified Rankin Scale, 
improvement in motor functions using the Fugl -Meyer scale, and 
improvement in cognitive status using a test battery (including Rey Complex Figure Test)  
• Increase in fluorodeoxyglucose (FDG) uptake measured by [CONTACT_147994] (PET)  
Safety 
Parameters  • SB623 - and surgical -related adverse events using WHO toxi city 
criteria  
• Adverse changes imaged by [CONTACT_418569] (edema, adverse anatomical 
changes)  
• Serious adverse events (SAEs) using WHO toxicity criteria  
• Serum chemistry and hematology  
Other 
Laboratory 
Parameters  • Serum levels of antibodies  to SB623 cells  and PBMC fu nction  assay  
• Development of serum antibodies to donor SB623 cells: HLA Class I 
(HLA -A*23:PWMV, HLA -A*68:CGBR; HLA -B*45:FJH, HLA -
B*53:KJW; or HLA -Bw4, HLA -Bw6; HLA -Cw*04:SSWB, HLA -
Cw*16:01); or Class II (HLA -DRB1 *13:NGUB, HLA -DRB1 *16:02; 
HLA -DQB1*05:CHZY, HLA -DQB1*05:BK; HLA -DQA1*01:DVB, 
HLA -DQA1*X, HLA -DRB3,4,5: 3*03:01, HLA -DRB3,4,5: 5*02:02)  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR01 Amendment 5.[ADDRESS_527946] countries in 
the world.2,3,4,5  In 2007, nearly 700,000 new or recurrent strokes and 160,000 stroke- related 
deaths were expected to occur in the [LOCATION_002].6,7  In addition, magnetic resonance 
imaging (MRI) studies reveal that nearly 22 million asymptomatic strokes occur every year.8  
Stroke is also a major cause of prolonged neurologic disability in adults,3,4,6,8,9 with an annual 
economic burden of over $[ADDRESS_527947]-stroke interventions focus on life support through respi[INVESTIGATOR_418535], monitoring oxygen saturation and blood glucose level, prevention of metabolic disturbances, maintenance of organ function, and management of elevated intracranial pressure.
15  The only approved therapi[INVESTIGATOR_130243] U.S. are 
thrombolytic agents, to be given within 3 hrs. of onset of the stroke.  It has been estimated that less than 5% of acute ischemic stroke patients receive this therapy, probably due to the stringent criteria for thrombolytic intervention, the patient arrival beyond the 3-hour window, and lack of adequate facilities at many hospi[INVESTIGATOR_600].
[ADDRESS_527948] shown that 90% of patients with ischemic stroke achieve no further improvement after about [ADDRESS_527949] so far been limited, with 
only three trials conducted and reported to date, with only two having used human cells. 
Fetal cells from the porcine lateral ganglionic eminence which had been shown to improve 
deficits in an animal model of Huntington’s disease,24,25 and in an animal model of middle-
cerebral artery occlusion26 were studied in a Phase 1 clinical trial.  Five patients with chronic, 
stable, moderate -sized basal ganglia infarcts received intrastriatal implantation of the cells.  
One of the patients developed a cortical vein occlusion, and the study was terminated by [CONTACT_56270] D rug A dministration .  Attribution of the adverse event has not been clarified.  
None of the patients showed improvement on the Modified Rankin Scale.
23 
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 12 of 85 Cultured human neurons derived from an embryonal carcinoma cell line that was isolated 
from a teratocarcinoma (LBS -Neurons) which had been shown to improve deficits in an 
animal model of middle -cerebral artery occlusion27 were studied in an open- label Phase 1 
clinical trial.28, Initially, 4 patients with stable stroke received stereotactic implants 2 million 
cells in one needle track into the area of infarction, divided into 3 implants with 20 µL per implant..  Subsequently, 8 additional patients were randomized to receive either single- pass 
(2 million cells in 3 implants) or 3 -pass (6 million cells in 9 implants) injections into  the area 
of infarction.  All patients also received cyclosporine A orally.  The outcomes were that the procedures and injections were well tolerated with a mean improvement in all patients by [CONTACT_418570] (ESS) that was statistically signific ant, and with an improvement in 
FDG -PET scans in half of the patients at 6 months. 
Based on the encouraging results from that Phase 1 study, an open- label, observer -blinded 
Phase 2 study was conducted with LBS-Neurons in 18 patients who were randomized between surgery with 5 or 10 million cells implanted (25 implantation sites) plus rehabilitation (14 patients), or rehabilitation alone (4 patients), with all surgical patients also receiving cyclosporine A orally.
29  The patient mix was approximately an equal number with 
ischemic or hemorrhagic stroke.  The outcomes were that both the proce dure and the cell 
implants were again well tolerated.  There was no statistically -significant improvement in the 
ESS between groups, although some improvements were found when patients were analyzed as their own controls.  Some cognitive improvements were also noted.  Finally, there were statistically -significant improvements in some of the Fugl-Meyer assessments, but not on 
overall motor function. 
2.2.4 Stereotactic Surgery 
In addition to the two studies referred to above with LBS Neurons, a retrospective study of 
over 2,650 patients who received stereotactic surgery over a 28- year period at one major 
clinic found an incidence of surgery-related complications to be <1%, establishing the high degree of safety for this procedure.  Complications reported included a need for a craniotomy 
for hematoma evacuation (0.36%), perioperative seizures (0.36%), burr hole infections (0.08%), and death (0.08%).
30 
2.3 Methods to Evaluate Severity of Stroke 
No one method has been shown to be adequately encompassing to evaluate the sever ity of 
stroke, since a constellation of symptoms is usually present.  Accordingly, neurologists use several methods to score neurological deficits, including standardized stroke scales such as the European Stroke Scale (ESS),
31 the National Institutes of He alth Stroke Scale 
(NIHSS),32,33 the Modified Rankin Scale (MRS),34,35 the Hemispheric Stroke Scale (HSS),[ADDRESS_527950] also been used.  
2.4 Rationale for Use of SB623 cells in Stroke 
2.4.1 Summary of SB623 Cells Properties 
SB623 cells are human bone marrow- derived cells and are being developed as an allogeneic 
cell therapy for chronic, stable stroke and other neurodegenerative conditions.  SB623 cells are generated under GMP conditions by [CONTACT_418571] (MASC) with a plasmid encoding the human Notch- 1 intracellular domain.
40  This 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 13 of 85 transfection is considered transient because the plasmid rapi[INVESTIGATOR_418536]/passaging of the cells.  Thus, the gene and its products which were initially detected at very low levels are not expected to be present at all after a short time post -
implantation.  
Unlike the MASC cells used to produce SB623 cells, the product has limited potentia l to 
differentiate into bone or adipose cells. 
2.4.2 Summary of Notch- 1 Gene Properties  
Notch -1 is involved in the regulation of the development process in many species, including 
humans.  Notch is a heterodimeric transmembrane receptor.  Its natural ligands (Se rrate, 
Jagged, Delta) are also integral membrane proteins, revealing a cell -cell or juxtacrine role for 
Notch.  Once stimulated by a ligand, Notch is proteolytically cleaved releasing the Notch 
IntraCellular Domain (NICD) from the plasma membrane.  Once re leased, the NICD 
migrates to the nucleus where it plays the role of an activating transcription factor for a number of genes. 
3.[ADDRESS_527951]  
This section includes a brief summary of preclinical data available on SB623.  Mor e detailed 
information can be found in the Investigator’s Drug Brochure for SB623 cells. 
3.[ADDRESS_527952] been transiently transfected 
with the intercellular domain of the human Notch -1 gene. 
3.2 Preclinic al Pharmacology 
3.2.1 In Vitro  
The in vitro  characterization of SB623 cells has included 8 basic areas: fate of SB623 cells, 
protection of primary neurons from Oxygen Glucose Deprivation, the secretion of 
neurotrophic factors, Notch-1 signal transduction, epi[INVESTIGATOR_14364], osteo - and 
adipogenesis, and anti-inflammatory properties of SB623.  See the Investigator’s Drug Brochure for details on these studies.  
[IP_ADDRESS] Protection from Oxygen/Glucose Deprivation 
Figure 1 shows the effects of SB623 co- culture on hippocampal slices.  Similar protection 
was observed using SB623 conditioned medium (not shown) Taken together, these results strongly suggest that SB623 cells secrete soluble fact ors that can protect neurons. 
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.[ADDRESS_527953] OGD.  SB623 cells were produced from 5 different donors.  
 [IP_ADDRESS] Trophic Factor Secretion  
The starting material for SB623 is bone marrow aspi[INVESTIGATOR_337], from which are isolated Marrow Adherent Stromal Cells (MASC) also known as Marrow Stromal Cells (MSC).  These cells have been extensively studied and are known to secrete a wide variety of factors.  Independent of MSCs, a variety  of factors have been shown to be implicated in beneficial 
effects for cerebral ischemia.  Figure [ADDRESS_527954] o f cytokines that were investigated.  
The ones in blue are secreted by [CONTACT_418572]623 and MSC.  The ones underlined are secreted by [CONTACT_144498]623 in much higher concentrations compared to MSC.  
Figure 2  Trophic Factors Released in Conditioned Medium  
•Custom antibody 
array (RayBiotech)
•[ADDRESS_527955] on the right show factors found in MASC and SB623 conditioned media (blue) and those preferentially produced by [CONTACT_144498]623 (underlined). 
 [IP_ADDRESS].[IP_ADDRESS]
[ADDRESS_527956]-OGD (hours)Fold Change in LDH Release
 vs. Matched ControlOGD Only
OGD + D1 SB623
OGD + D2 SB623
OGD + D3 SB623
OGD + D4 SB623
OGD + D5 SB623
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 15 of 85 [IP_ADDRESS] Extracellular Matrix Secretion  
SB623 c ells have been shown to secrete beneficial extracellular matrix in culture with rat 
neural cells, as measured by a increase in growth of intact cells.  This is illustrated in Figure 
3 below. 
Figure 3 SB623 Cells Secrete Beneficial Extracellular Matrix  
 
020406080100120140160180
0 5 10 15 20 25
Days of cultureLDH, mUMSC-ECM
SB623-ECM
PDLA
ECM PDLB
MASC -ECM
 
Panel A shows cell mass (as Lactate Dehydrogenase) vs. days in culture. Poly-D- lysine 
(PDL) serves as a control. Panel B show a photomicrograph from MASC. SB623 and PDL respectively.  
 In this experiment, culture of MSC or SB623 with poly-D lysine as control resulted in secretion of matrix.  When rat neuronal cells, including glia, were allowed to grow on the matrices, the rate growth was much faster with SB623 matrix compared to MSC -matrix, as 
measure by [CONTACT_418573] a surrogate.  As seen in B of the figure, both SB623 matrix and MSC matrix resulted in rat neurons Secretion of Matrix  
 [IP_ADDRESS] Epi[INVESTIGATOR_418537]623 cells are produced by [CONTACT_418574].  A stable phenotypic 
change in the absence of a change in the genomic sequence is defined as epi[INVESTIGATOR_18193].  There are a wide variety of epi[INVESTIGATOR_418538].  These include covalent modifications (acetylation, methylation, etc. ) of 
the N -terminal “tails” of the histones, creating more or less densely packed chromatin and 
thereby [CONTACT_418575].  This is one of the basic mechanisms 
controlling gene expression.  Another form of epi[INVESTIGATOR_418539].  The sequence CpG is underrepresented in the genome.  There are enzymes that can methylate the 5 position of cytosine de novo  and others that complete the methylation of 
hemi -methylated CpG/GpC basepairs, creating a heritable mark.  There are high densities of 
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 16 of 85 CpGs near the promoters of about half of the genes in the human genom e.  These CpG 
“islands” are typi[INVESTIGATOR_418540].  When the CpG island of 
a particular gene becomes hypermethylated, chromatin density increases and down -regulates 
the expression of that gene. 
SB623 cells have an altered developmental potential when compared to the MASC source 
cell.  We reasoned that the pattern of CpG methylation might be different in SB623 vs . 
MASC.  In ongoing work with a contract research laboratory (Epi[INVESTIGATOR_418541], GmbH, Berlin), we performed bisulfite sequencing on CpG islands associated with a collection of candidate genes.  The results are shown in Figure 4.  
Figure [ADDRESS_527957]- bisulfite 
conversion repeals the number of methyl -Cs present in the  amplicon. The degree of 
methylation is indicated by [CONTACT_68458] (yellow = completely unmethylated, blue = 100% methylated. White bars mean no sequence could be obtained. MASC (control) and SB623 (target) from three different donors were compared. 
 

SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 17 of 85 Figure 4 reveals that 4 of the 5 genes examined (LRKK1, ROPN1L, IGF2R and SDF4) are 
more methylated in SB623 than in MASC.  One gene (DNMT3b) is less methylated in SB623 compared to MASC. 
We are currently looking more globally at DNA methylation.  If this pattern holds, (increase methylation in SB623) we can conclude that SB623 cells are more differentiated than MASC.  This should also lead to candidate genes to help explain SB623 properties at a molecular level.  
[IP_ADDRESS] Effects on Osteogenesis and Adipogenesis 
MASCs are also known as Marrow Stem Cell because of their ability to differentiate into tissues derived from the embryonic mesenchyme, specifically bone, cartilage and adipose.  We compared the osteogenic and adipogenic potential of SB623 to MASC using standard differentiation protocols. 
After several weeks of differentiation, the osteogenic cells were stained for bone formation 
with alizarin red and the adipogenic cells stained for fat with Oil Red O.  The results are shown below in Figure 5. 
Figure 5 Differentiation potential of MASC and SB623  
 
Cells were g rown in osteogenic and adipogenic media (plus or minus BMP6) for several 
weeks and then stained with Alizarin Red (bone) or Oil Red O (fat).  
 
MASC cells readily differentiated in to bone and adipose as expected.  On the other hand, 
SB623 cells are dramatic ally attenuated in their ability to differentiate into these tissues.  
This has been demonstrated for multiple lots of SB623 (not shown).  These finding suggest that SB623 may be less likely than MASC to form ectopic bone or fat after implantation in vivo. 
[IP_ADDRESS] Anti-inflammatory and Immunosuppressive Properties  
Bone marrow stromal cells, also known as mesenchymal stem cells (MSCs) or marrow -
adherent stem cells (MASCs) are known to have anti -inflammatory and immunosuppressive 
properties.  Since SB623 cells are derived from MASCs, the anti- inflammatory and  
immunosuppressive properties of these cells w ere assessed.  In a Mixed Lymphocyte 

 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 18 of 85 Reaction (MLR), immune cells from two unrelated donors are mixed and immune cell 
activation and proliferation are measured as an indicator of adaptive and innate immune activity.  The results from this experiment demonstrated that, in the presence of SB623 cells, the activation and proliferation of T cells is attenuated.  In another series of experiments the effects of SB623 on dendr itic cell formation was measured, since dendritic cells are the 
primary initiators of the T cell response in the MLR.  To assess the impact of SB623 cells on dendritic cells, a co -culture assay between immature dendritic cells and SB623 cells was 
performed .  The results demonstrated that SB623 cells reduce the levels of co- stimulatory 
molecules on dendritic cells.  Collectively, these anti-inflammatory and immunosuppressive properties may contribute to SB623’s regenerative properties and seem to obviate the need for immunosuppressive drugs during SB623 therapy. 
3.2.2 In Vivo Stroke Models 
[IP_ADDRESS] Study N-030 
Therapeutic Benefits of SB623 in Experimental Stroke SB623 cells or vehicle were implanted into the striatum of male Sprague- Dawley rats that 
had been stroked with the MCAo procedure in the right hemisphere, and immunosuppressed 
with CsA, 10 mg/kg/day i.p.  At [ADDRESS_527958]-stroke, 3 groups of 10 animals each were implanted with either 90,000 SB623 cells (low dose), 180,000 SB623 cells (high dose) or an equivalent volume of sterile buffer alone (vehicle).  Rats were immunosuppressed throughout the planned one-month post- transplantation survival time.  Behavioral measurements were 
made pre -stroke, immediately post-stroke, and at [ADDRESS_527959]- transplantation, the animals treated with SB623 cells 
showed significant behavioral improvement (p≤0.[ZIP_CODE]) with both the elevated body swing test and the Bederson score compared to the control group, with the higher dose of SB623 cells suggesting a trend of improvement compared to the lower dose.
41  See Figure 6 and 
Figure 7. 
Histological evaluation of the brain at 28 days using the anti-human nuclear antibody HuNu 
showed 7-9% cell survival.  Staining with MAP2, a neuronal marker along with HuNu showed that < 1% of the cells had differentiated along a neural pathway.  Nissl staining revealed a significant rescue of the ischemic penumbra, with 45% cell loss in the control animals and 20% in the treated animals, regardless of dose (p<0.01). 
Overall, the positive behavioral outcomes and the relatively low number of engrafted cells in 
this study point more to a trophic support mechanism rather than to one of cell replacement. 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR01 Amendment 5.[ADDRESS_527960]: 1- Month Rat Study  
 
 
The Elevated Body Swing Test shows SB623 cells promote stroke recovery. Pre- stroke the 
animals had no rotational bias after lifting by [CONTACT_418576] (50%).  The animals showed typi[INVESTIGATOR_418542] -stroke (near 100%) bias.  Low dose (90,000 S B623 cells) 
and high dose (180,000 cells) improved over the course of the 28 day study . 
 
Figure 7  Bederson Neurologic Exam : 1-Month Rat Study  
 
SB623 cells at both doses caused an improvement in the multicomponent  Bederson 
neurological score post -stroke. 
 [ADDRESS_527961] 
Stroke  7 Day  14 Day  28 Day  Rotational Bias (%)  High Low Vehicle  
[ADDRESS_527962] 7 day  14 day  28 day  Bederson Score High 
Low 
Vehicle  Bedrson Score  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 20 of 85 Figure 8 Comparison of SB623 and MSC in MCAo Rat Model 
Balance Beam
Saline
SBMSC
SalineSBMSCLimb Placing
Morris Water Maze
(Memory Component)
Saline                     SB                     MSC
Mimura et al. (2005) J. Neuropathol . Exp. Neurol. 64:1108 -1117
 
A published study comparing MASC (MSC) and rat-derived SB623- like cells shows 
superior benefit in balance beam, limb placing and Morris water maze.  
[IP_ADDRESS] Study N-[ADDRESS_527963] -
MCAo stroke with either 90,000 SB623 cells (low dose), 180,000 SB623 cells (high dose) or 
an equivalen t volume of sterile buffer alone (vehicle).  Rats were immunosuppressed daily 
with cyclosporine A (CsA, 10 mg/kg, i.p.) throughout the planned three-month post-transplantation survival time.  Behavior evaluations were conducted monthly through month 3.  At [ADDRESS_527964]: 3- Month Rat Study  
 
SB623 cells show enduring benefit in EBST scores over 3 months. A trend in dose response is evident.  5060708090100110
Baseline Pos t-
stroke1 Month 2 Months 3 MonthsRotational Bias (%)Vehicle
Low  Dose
High Dose
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 21 of 85 Figure 10  Bederson Neurologic Exam: [ADDRESS_527965] -stroke 
performance of the animals revealed significant impairments in both tests (p’s < 0.0001) in 
all stroke animals included in this study.  
Following random assignments of the stroke animals to either vehicle, low dose 90,000 SB62 3, or high dose 180,000 SB623, ANOVA revealed significant effects for both tests (p’s 
< 0.0001).  Those that received the high 180k SB623 or low dose 90k SB -623 displayed 
significant attenuation of behavioral deficits in both tests compared to vehicle -treated stroke 
animals (p’s < 0.0001).  This behavioral recovery by [CONTACT_144498] -[ADDRESS_527966] -fixed in formalin in PBS followed by [CONTACT_418577].  
Thereafter, cryostat sectioned tissues were obtained.  Coronal sections from the ischemic striatal penumbra in each animal were stained with Nissl, a marker of ischemic cell death.  Examination revealed that the stroke animals that received vehicle alone exhibited abundant ischemic cell death characterized by  [CONTACT_418578].  The 
stroke animals that received low or high dose SB -623 cells displayed obviously fewer 
numbers of ischemic cells, indicating reduction in ischemic cell death in these transplanted animals.  Free -floating sec tions were incubated with the antibodies MAP2 (a marker of 
immature neurons) and HuNu (a marker of human cells). Brain sections from each group (i.e., months 1, 2, and 3) showed the presence of human cells.  Samples from the higher -dose 
groups showed more double -labeling that those from the lower -dose groups.  A small 
percentage of the HuNu -positive cells also stained positive with NeuN, a maker of mature 
neurons.  None of the HuNu- positive cells stained positive with the glia marker GFAP.  

 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 22 of 85 [IP_ADDRESS] Study N-035 
Thera peutic Benefits of SB -623 in Experimental Stroke with/without CsA: 6-mo. Study42 
SB623 cells were implanted into the striatum of male Sprague -Dawley  rats at [ADDRESS_527967] -
MCAo stroke with 180,000 SB623 cells or an equivalent volume of sterile buffer alone 
(vehicle) , with two control groups.  One group of cell -treated rats and one group of control 
rats were immunosuppressed daily with cyclosporine A (CsA, 10 mg/kg, i.p.) throughout the planned six -month post- transplantation survival time .  Similarly, one group of cell -treated 
rats received no CsA and one group of control rats received no CsA.  Behavior evaluations were conducted monthly through month 6.  At [ADDRESS_527968].  Similar significant results were also obtained for the Forelimb Akinesia, Paw Grasp, and Balance Beam tests.  See the Investigator’s Drug Brochure for further details.  
Histological evaluation of the brains of the s troke animals that received  SB623 or vehicle, 
with or without immunosuppression displayed no eventful inflammation or immune 
response.  T here was  no obvious difference between vehicle treatment  groups and 
transplanted groups, indicating that such increased immunoreactivity was due to the stroke 
insult and not the transplants.  Further, the intensities of immunoreactivity of the astrocyte marker  GFAP, the leukocyte marker  CD11b, the macrophage/mic roglia marker Iba1, and the 
T cell marker  CD3 were comparable across all treatment groups.  The lack of differences in 
these inflammatory and immune markers across groups clearly indicates that intracerebral 
transplantation of human SB623 cells in stroke rats did not elicit overt host reaction.  Moreover, these observations also reveal that immunosuppression is not needed to prevent inflammatory response of the host tissue following SB623 transplantation. 
SB623 cell grafts  did not reduce the extent of core cerebral infarction, the transplants 
significantly enhance the survival of host cells in the peri- infarct area (Figures 7 -12).  In view 
of graft survival being sporadic at [ADDRESS_527969]-transplant ation (Figures 13 -14), the 
plausible mode of action of SB623 grafts in promoting behavioral recovery and histological 
rescue of the peri -infarct area is likely not via cell replacem ent but due to secretion of growth 
factors by [CONTACT_418579]623- stimulated host tissue . 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 23 of 85 Figure 11 CsA is not Needed for Long -Term Improvement of Stroke Deficits  
Notes: 
•n=10 per treatment group
•Control data from stroke animals that received intrastriatal vehicle infusion and treated with i.p. vehicle or CsA
•Data are means +/- standard deviationEBST
020406080100120
1 2 3 4 5 6 7 8
Time Period% Biased Swing ActivityControl
SB623+CsA
SB623+Veh
Baseline Month [ADDRESS_527970] -
StrokeMonth 6 Month 4 Month 5
 
The conclusions were:42 
For behavioral recovery in stroke animals following SB623 transplants: 
• Recovery of motor and neurologic functions in stroke rats was sustained up to [ADDRESS_527971]-transplantation, which appeared to improve over time 
• Immunosuppression was confirmed to be not critical in promoting and maintenance 
of behavioral improvement in ischemic stroke rats  
• No overt behavioral or gross physical side effects in any of the rats enrolled in this long- term study  
For host tissue inflammatory and immune status following SB623 transplants: 
• There is no observable eventful inflammation or immune response between control and transplanted stroke animals, with or without C sA. 
• Overall, the ipsilateral stroke side appears to display slightly higher immunoreactivity across all markers compared to the contralateral non stroke side.  
• There is no obvious difference between control groups and transplanted groups, indicating that such increased immunoreactivity in inflammatory and immune 
markers in the ipsilateral stroke side is due to the stroke insult and not the vehicle infusion or cell transplant.  
For rescue of stroke brain following SB623 transplants: 
• There is no observable difference in the volume of infarction with or without transplants, and also with or without CsA.  
• However, when the number of surviving cells is counted within the peri- infarct area, 
transplanted stroke animals displayed significantly higher cell survival than vehicle-infused stroke animals. 
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 24 of 85 • The rescue of ischemic peri -infarct area by [CONTACT_418580]623 cells was not 
affected by [CONTACT_256204], in that with or without CsA, the transplants 
increased cell survival in the peri -infarct area.  
For SB623 graft survival in stroke brain: 
• Using human specific antigen antibody, HuNu, we did not detect robust graft survival 
at [ADDRESS_527972]-transplantation.  Only sporadic HuNu positive cells (1- 5) in each 
transplanted brain were observed  
• This observed minimal graft survival was not affected by [CONTACT_256204], in that with or without CsA, we only detected a few HuNu positive cells in those stroke 
animals that received SB623 transplants.  
3.[ADDRESS_527973] other cells from hypoxic injury, as shown with 
primary neurons and hippocampal slices (see Sections  [IP_ADDRESS] and [IP_ADDRESS]).
43  These factors 
may provide trophic support to damaged cells in vivo .  In addition, SB623 cells secrete 
matrix that provides support for neural cell growth.44  Additional investigation into the 
mechanism is ongoing. 
3.4 ADME  
All available evidence to date indicates that SB623 cells stay within the brain, with no 
evidence for any movement outside the brain.  See below study summary. 
Cells implanted in brains are not detectable beyond 1 month in athymic nude rats (see 
Section s 3.6.1 and 3.6.2) or in immunosuppressed normal Cynomolgus monkeys at 1 month 
(see section 3.6.6).  Studies with SB623 in rat models of stroke found approximately 7- 9% of 
implanted cells survived at 1 mo., with < 1% differentiated along a neural pathway (see Section 3.2.2).  This is consistent with results also from a study in a rat model of Parkinson’s disease,
45 in w hich less than 1% of intrastriatal-implanted SB623 cells survived at [ADDRESS_527974]- implant.   In another study using the stroke rat, cells were not detectable in the brain at 6 
mos., regardless of whether the animals had been treated with CsA or not. 
3.4.1 PSP021 (N -032) 
A [ADDRESS_527975]- implantation.  The injection paradigm was evaluated for 
potential toxicities in preparation for proposed safety studies in the non-human primate.  A method of localizing implanted human SB623 cells was also confirmed in this study. 
Histological examination of the brain included using Y-chromosome in situ  hybridization (Y-
ISH) staining.  Figure [ADDRESS_527976] a blue background. The needle track is shown.  Figure 13 Primate Y -ISH Staining  
 
A close-up of Y-ISH staining of SB623 cells implanted in primate brain.  
 
 
3.4.2 MPI 1295-001 
Implantation of SanBio Cells Into the Brains of Athymic Nude Rats: A Short- Term  
Biodistribution Study  
The purpose of this study was to test the implantation procedure in athymic rats; determine the post-implantation survival of SB623 cells and the growth of human HT1080 fibrosarcoma cells in the brains of athymic nude rats, and to develop a method of detecting the implanted SB623 cells. 
Each rat was mounted in a stereotaxic instrument .  Bilateral injections of cell suspensions 
were made into the cortex and striatum.  Four small holes were drilled in the skull at the 
required coordinates
47 of both the right and left hemispheres (1 cortex and 1 striatal hole per 
hemisphere).  Nine days after surgery, there were two animals in Group 2 (HT1080 fibrosarcoma cells) found dead in their cages.  The remaining two animals in this group w ere 
observed to have impairment that made it necessary for them to be euthanized in extremis .  
All animals in this group were submitted to necropsy in accordance with the protocol.  

 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 26 of 85 Sixteen days after surgery, all four animals in Group 1 (SB623 cells) were submitted to 
necropsy.  No abnormal findings in animals receiving SB623 were observed clinically, 
macroscopi[INVESTIGATOR_897], or microscopi[INVESTIGATOR_897].  No SB623 cells were found in the brain at [ADDRESS_527977] implantation. 
A total of 8 rats were used in this study. SB623 cells were stereotaxically implanted into the 
brains of adult male athymic male rats. Rats were transplanted bilaterally into identical sites  
in the dorsolateral striatum with approximately 36,000 to 42,000 SB623 cells in 2 uL of modified 1X Dulbecco’s phosphate -buffered saline without calcium or magnesium, (DPBS 
w/o Ca+Mg).  Rats were sacrificed at 5h, 48h and 14d post implantation. Cell survi val and 
migratory capacity at the implant site was determined by [CONTACT_418581]623 cells in perfused sections using human nuclear antigen immunocytochemistry.  Sections were counterstained with Nissl or hemotoxylin eosin.  
Survival, determined by [CONTACT_418582] ( HuNu ) antigen staining at [ADDRESS_527978]-implantation, was 16.7% and 9.6%, respectively.  Survival at 14 days was 8.2%.  
This study confirmed that the SB623 cells transplanted to the striatum of the nude rat have the capaci ty to survive at acute time points.  Furthermore, there was no evidence of extensive 
migration of implanted SB623 cells.  
3.4.4 N-033 
A 2-Day Study SB623 Cells Implanted Into The Brains Of Adult Male Athymic Rats; a 
Comparison of DPBS and Plasma- Lyte A as Formulation Buffers and the Effects of 
Increased Delivery Rates/Volumes  
This study was designed to justify the change from formulation in Dulbecco’s Phosphate Buffered Saline (DPBS) to Plasma- Lyte A USP and to determine the impact of doubling the 
dose, volume and implantation rate to determine if these increases can be used in a planned rat safety study.  SB623 cells were implanted bilaterally into the striata of adult male athymic rats and were assessed histologically at [ADDRESS_527979] contribut ed to increased tissue damage and a decreased cell 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 27 of 85 survival seen in this study compared to previous studies.  In addition, the faster rate of cell 
infusion (2 µL/min vs.  1 µL/min) used in the present study may have contributed to apparent 
compression damage in the host tissue. 
We conclude that while doses of 230K cells can be injected into single tracks in the adult rat 
striatum, these volumes and/or injection rates are not optimal for maximum survival of SB623 cells in vivo  and appear to be associated with  host tissue damage.  
The use of DPBS versus Plasma- Lyte A to formulate the cells demonstrated small qualitative 
differences in the morphology of the cells within the graft core.  However; there were no demonstrated significant differences in cell survival in vivo  or in the in vitro stability of the 
cells following incubation at room temperature for at least 4 hr.  
3.5 Overall Preclinical Pharmacology and ADME Summary 
Results of all the preclinical pharmacology and ADME studies with SB623 are summarized in Table 1 below. 
 
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14      Page 28 of 85 Table 1 Summary of Preclinical Pharmacology and ADME Studies 
Animal Species/Model  Study Type  SB623 Dose, Route  Results  Study Reference  
Normal Animal  
Athymic nude rat  
8 Animals randomized 
into 2 groups 16-day pi[INVESTIGATOR_418543], survival and safety of SB623 cells compared  
to HT1080 fibrosarcoma cells  0.5 million SB623 cells 
total dose/animal 
One time administration  
Half into each hemisphere, divided into 60% striatum 
and 40% cortex  No abnormal findings in animals 
receiving SB623  
SB623 cells were found in the brain at [ADDRESS_527980]- implant 
HT1080- treated animals died or 
were in extremis by [CONTACT_4475] 9  MPI 1295 -[ZIP_CODE] 
(SanBio PSP010)  
Athymic male rat  SB623 in vivo  survival  36-42,000 SB623 cells 
total dose/animal 
One time administration  
Half into each hemisphere 
into striatum  No abnormal findings in animals 
receiving SB623  
The percentage survival decreased from 16.7% to 8.2% over 14d. 
No evidence of extensive migration  N-029 
(SanBio PSP006) 
Nude rat  Pi[INVESTIGATOR_418544] 
Y-ish assay  In vitro  assay development  Y-ish assay is usable for detecting 
SB623 from male human donors in 
either rat or monkey tissue  N-031 
(SanBio PSP028) 
Athymic male rat  Rat survival of cell lot 
used in the MPI [INVESTIGATOR_418545] 233,000 cells/hemisphere 
in either Plasma -Lyte A or 
DPBS into striatum Some tissu e damage with both 
vehicles, concluded to be due to larger injection volume and/or more rapid rate of infusion compared to other studies 
No differences in cell survival between the vehicles in vivo  or up to 
4 hr. in vitro  N-033 
(SanBio PSP005)  
 
SanBio, Inc.      Confidential and Proprietary  
 
Protocol SB -STR01  Amendment 5.0 11- Sep-14      Page 29 of 85 Animal Species/Model  Study Type  SB623 Dose, Route  Results  Study Reference  
Cynomolgus Monkey  
Immunosuppressed with 
CsA  Pi[INVESTIGATOR_418546]623 survival  One-time administration  
Total 5.8 million cells per hemisphere in 4 needle tracks in either cortical or subcortical areas)
 Minimal evidence of cell death or 
necrosis of the host tissue 
No local or systemic toxicities at 7d  
SB623 cells pers ist for at least 7d by 
Y-ish assay  N-032 
(SanBio PSP021) 
 
Stroke  
Sprague -Dawley Rat  
MCAo Stroke 
Immunosuppressed with 
CsA Biodistribution  180,000 cells 
stereotactically implanted into the striatum Using qPCR, no SB623 cells were 
found in spleen, lung, heart, liver, kidney, and testes of stroked animals 2 weeks after implant  Althea 7 -RT-
SB0102 
(SanBio PSP034) 
Sprague -Dawley Rat  
MCAo Stroke 
Immunosuppressed with 
CsA 7-day, [ADDRESS_527981]-MCAo, intrastriatal in right hemisphere Statistically -significant (p≤0.0001) 
improvement with both doses compared to control in both the elevated body s wing test and 
Bederson score at all time points.  
Cell survival ranged from 5 -7% for 
the two dose levels at 28 days, with < 1% expressing the neuronal marker MAP2.  
Implantation of SB623 cells resulted in a significant rescue of the ischemic penumbra compared to control (p<0.01) regardless of dose. N-[ZIP_CODE] 
(SanBio PSP007) 
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14      Page 30 of 85 Animal Species/Model  Study Type  SB623 Dose, Route  Results  Study Reference  
Sprague -Dawley Rat  
MCAo Stroke 
Immunosuppressed with 
CsA   1-mo., [ADDRESS_527982]-MCAo, intrastriatal in right 
hemisphere  Statistically -significant (p≤0.0001) 
improvement with both doses compared to control in both the elevated body swing test and Bederson score at all time points.  N-[ZIP_CODE] 
(SanBio PSP027) 
Sprague -Dawley Rat  
MCAo Stroke 
Comparison 
with/without CsA  1-6-mo. Efficacy, cell 
survival and safety  
Vehicle controls  One-time administration  
180,[ADDRESS_527983]-MCAo, intrastriatal in right hemisphere Statistically -significant (p≤0.0001) 
improvement with both doses compared to control in all motor/neurological measures at all time points.  
No inflammatory response 
attributable to the SB62 [ADDRESS_527984] been conducted: a 12- mo. tumorigenicity 
study in athymic nude rats, a 4-mo. bridging study in at hymic nude rats, and a 6 -month study 
in immunosuppressed Cynomolgus monkeys. 
3.6.1 12-Month Rat Tumorigenicity 
(Study number 1295- 002; MPI [INVESTIGATOR_133720])  
The purpose of this GLP study was to assess the possible tumorigenicity of SB623 cells after 
stereotactic implantation into brains of nude rats.  A total of 5 X 105 SB623 cells or vehicle 
were administered into the striatum and cortex of both hemispheres of a total of 120 athymic nude male and female rats further immunosuppressed with the rabbit anti- NK cell antibody  
Anti-Asialo GM1 (GM1Ab), with observations up to [ADDRESS_527985]-implantation.  Two 
implantations were done in each hemisphere with 10 µL per hemisphere (20 µL per animal): 6 µL into the striatum and 4 µL into the cortex.  Animals (15 each per group per se x) were 
sacrificed at [ADDRESS_527986]- implant.  
The endpoints of the study were: clinical observations; clinical pathology at termination; histology of major organs (including brain); cellular markers for presence of SB623, phenotype expression, and inflammation/immune responses.  
No SB623 cells, as determined from an anti-human mitochondrial antibody, were found at [ADDRESS_527987] 
and/or chronic inflammation was noted in [ADDRESS_527988] article relationship was considered unlikely. 
3.6.2 4-Month Rat Tumorigenicity Bridging Study 
(Study number 1295- 008; MPI [INVESTIGATOR_133720])  
The purpose of this GLP study was to assess the possible tumorigenicity and survival of 
SB623 cells after stereotactic implantation into brains of nude rats using identical procedures as with study 1295- 008 above , except without a control group.  A total of 5 X 10
5 SB623 
cells were administered into the striatum and cortex of both hemispheres of a total of 30 athymic nude male and female rats further immunosuppressed with the rabbit anti- NK cell 
antibody Anti- Asialo GM1 (GM1Ab), with observations up to [ADDRESS_527989]- implantation.  
Two implantations were done in each hemisphere with 10 µL per hemisphere (20 µL per animal): 6 µL into the striatum and 4 µL into the cortex.  Animals (3 per sex per time point) were sacr ificed at [ADDRESS_527990] been no adverse cell -related findings in clinical observations or clinical 
pathology.  Histological examination of the brain has shown no abnormalities that could be 
attributed to SB623 cells.  Since cells were found to be present only at the 2-wk. time point, the biological relevance of these findings beyond 2 wks. may be inconclusive. 
3.6.3 CsA Dose Selection for Monkey Safety Study 
The dose of cyclosporine was based on results of a pharmacokinetic study of i.m. 
cyclosporine in Cynomolgus monkeys ( see Section 3.6.4 below), and a supporting 
subsequent study also in Cynomolgus monkeys (see Section 3.6.5 also below) . 
3.6.4 Study Number MPI- 004; MPI [INVESTIGATOR_418547] i.m. daily at 15 mg/kg for 4 days.  Blood samples for analysis of cyclosporine levels were taken at 0 hr., 1 hr., 2 hr., 3 hr., 5 hr., 8 hr. 12 hr., and 24 hrs. on days 1, 2, and 3 at 24 hrs.  Mean trough levels ranged from 463 ng/mL (day 1) to 758 ng/mL (day 3).  The conclusion was that a dose of 15 mg/kg i.m. in the Cynomolgus monkey would provide adequate blood levels for the planned safety study with trough levels remaining relatively constant.  
3.6.5 One-Month Cynomolgus Monkey + -CsA 
(Study number S08-[ZIP_CODE], Valley Biosystems and MPI [INVESTIGATOR_133720])
52 
Two groups of 2 animals each were implanted with SB623 at a dose of 5 X 105 cells or 
vehicle.  The striata of the left and right hemispheres of each animal received two injection tracts of 100 µL each consisting of five 20- µL implants.  The right hemispheres of each 
animal received the cells, while the left he misphere received vehicle only.  One group of 
animals also received Cyclosporine A, 15 mg/kg/day I.M. beginning two days prior to surgery, while the other group received an equivalent amount of vehicle i.m. with the same schedule.  
There were no clinical sy mptoms in the animals that could be attributed to SB623.  There 
were also no adverse hematology or serum chemistry findings that could be attributed to SB623.  The brain histological findings were that no SB623 cells were found at 1 month.  Further, no his tological differences were seen between the brains of any of the animals, or 
between the hemispheres of each animal.  
The conclusions were that immunosuppression in this animal model did not prevent clearance of SB623 by [CONTACT_418583]. 
3.6.6 6-Month Toxicity: Cynomolgus monkey 
(Study number 1295- 005; MPI [INVESTIGATOR_133720])  
The purpose of this GLP study was to assess the overall safety of SB623 after stereotactic 
implantation into brains  of Cynomolgus monkeys.  A total of 5 X 10
6 SB623 cells or vehicle 
was implanted each into the cortical left hemisphere and the subcortical right hemisphere in 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 33 of 85 
 12 normal female Cynomolgus monkeys, immunosuppressed with daily i.m. cyclosporine 15 
mg/kg, with observations up to [ADDRESS_527991]- implantation.  
Each hemisphere received 2 injection tracks, with each track consisting of two sites, each receiving 50 µL, for a total of 200 µL per hemisphere (5 million cells or vehicle), using a concentration of 25,000 cells/µL or vehicle.  Animals (1 control, 3 cells each) were sacrificed at [ADDRESS_527992]- implant.  
The endpoints of the study were: clinical observations; clinical pathology at 2 weeks, 1 mo., 3 mos., and 6 mos.; histology of major organs (including brain); and cellular markers for presence of SB623, phenotype expression, and inflammation/immune responses. 
No SB623 cells, as determined from an anti-human antibody or a Y-ish assay, were found at 
1, [ADDRESS_527993].  
3.7 Summary of Preclinical Safety Studies  
See below Table 2 below.
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14      Page 34 of 85 Table 2 Summary of Preclinical Safety Studies  
Study Referenc e Study Description  Group Size 
(Species, sex)  Duration/Dose  Route of Admin.  Results/Conclusions  
MPI 1295 -002 
(N-007) Rat tumorigenicity 
study: 6 mos. and 12 
mos. evaluation; athymic nude rat receiving anti -asialo 
antibody  60 males: equal 
control and cells  
60 females: equal control and cells One-time administration  
Total 0.5 million cells per animal (0.25 million per hemisphere, with 60% in striatum and 40% in cortex in each hemisphere)  Striatum and cortex  No tumors at either 6 
mos. or 12 mos. 
No cell -related adverse 
findings during the study or at 6 mos. or 12 mos. 
No SB623 cells were 
seen at 6 mos.  
MPI 1295 -008 Rat tumorigenicity 
bridging study: 1 mo., 2 mos., 3 mos., and 4 mos. 30 animals: 3 per 
sex per time point  One-time administration  
Total 0.5 million cells per animal (0.25 million per hemisphere, with 60% in striatum and 40% in cortex in each hemisphere)  Striatum and cortex  No tumors at any time 
point to date (3 mos.)  
No cell -related adverse 
findings.  
SB623 cells were seen at 2 wks. but not at  1 
or 2 mos.. 
S08-[ZIP_CODE]  One-month pi[INVESTIGATOR_418548]623 survival comparing with/without CsA at 15 mg/kg/day i.m.  4 females  One time administration 
with or without CsA  
Total 5 million cells in the right hemisphere striatum and vehicle in the left hemisphere striatum using 2 injection tracts each with 5 implants.  Striatum  No SB623 cells were 
found at 1 month. 
No adverse clinical, laboratory, no histological findings attributable to SB623.  
No histological differences in the 
brains or hemispheres  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR01  Amendment 5.0 11- Sep-14      Page 35 of 85 Study Referenc e Study Description  Group Size 
(Species, sex)  Duration/Dose  Route of Admin.  Results/Conclusions  
MPI 1295 -005 
(N-018)  Cynomolgus monkey 
safety study: 1 mo., 3 
mos., and 6 mos. evaluation  
CsA at 15 mg/kg i.m. daily
 9 females with 
cells 
3 females with control vehicle
 One-time administration  
Total 10 million cells per animal (5 million cells per hemisphere in either cortical or subcortical areas)  Subcortical right 
hemisphere or cortical left hemisphere  No tumors at [ADDRESS_527994] and 5 cell deposits per track at 
varying depths, with 20 µL per deposit.  Concentrations of cell suspensions to be used will vary depending on the total dosage required per patient.  See Table 3 below. 
Table 3 Dosages, Volumes and Cell Concentrations 
 Total 
SB623 
Cells/Pt.  Total SB623 
Cells/Deposit  Total SB623 
Cells/Track  Concentration 
of SB623 
Cells per 
Injection  Total Volume 
per Deposit, 
per Track, 
and Total  
Cohort 1 2.5 X 106 1.65 X 105 8.25 X 105 8.3 X 106 
cells/mL  20 µL, 100 
µL, and 300 
µL 
Cohort 2: 5.0 X 106 3.3 X 105 16.5 X 105 17 X 106 
cells/mL  20 µL, 100 
µL, and 300 
µL 
Cohort 3 10 X 106 6.6 X 105 33 X 105 33 X 106 
cells/mL  20 µL, 100 
µL, and 300 
µL 
 
4.2 Justification 
Based on the animal pharmacology and safety studies (see Sections 3.2 and Section 3.6 
above), particularly the primate study that used 10 million cells/animal, and considering the 
larger brain mass of humans, a maximum dose of [ADDRESS_527995] a good chance of showing some efficacy.  The range of doses, as low as  2.5 X 10
6 SB623 cells, is considered necessary to 
observe any possible dose-response trends.  The stereotactic surgery procedure to be used (see Section 7.0) has been shown to be safe and well tolerated in another similar study
29,54, 
and in a retrospective study.[ADDRESS_527996]-stroke was chosen to allow for stabilization of 
motor deficits, particularly after physical therapy , and to allow a sufficient number of 
patients for reasonable accrual .  The duration of time needed for stabilization will vary by 
[CONTACT_4676], with >95% stabilized  at [ADDRESS_527997]- stroke.30  Entry criteria to this study require 
demonstration of stable motor deficit(s) during the prior 3-week period. 
5.[ADDRESS_527998] of the toxicity studies summarized in Section 3.6 used CsA, this was done to maximize the chances of uncovering any possible tumorigenicity properties of SB623.  Subsequently, it was found that the presence of CsA was not relevant for the pharmacologic activity of SB623 in the MCAo stroke rat model (see Section 3.2.2).  Although this is a xeno-transplant model, these findings suggested a need to re- evaluate the 
need for CsA in all future studies, including clinical.  The other animal toxicity studies also indicated that even in immunosuppressed models, SB623 did not survive beyond a month or so, indicating clearance by [CONTACT_418584].  Finally, an in vitro  study has shown that SB623 possesses anti -inflammatory and 
immunosuppressive activity (see Section  [IP_ADDRESS]) , thus suggesting the possibility that lack of 
use of CsA may not result in an adverse inflammatory response or any adverse cell -mediated 
immune response.  Nevertheless, careful monitoring will be done to unsure safety of the patients (see below).  
5.2 Monitor ing for Humoral or Cell- Mediated Immune Response  
In the Ph. 1/2a clinical study, Patients will be evaluated on Day 8 after implantation , monthly 
thereafter through month 4, and then at months 6, 9, 12 and 24 for any symptoms of inflammation, humoral immune response, or cell-mediated immune response (see Table 4) .  
The parameters to be followed are: vital signs, hematology, serum chemistry , lipid panel, 
cytokine levels (TNF- α, IL -6, IFN -γ), CRP, head MRI, antibodies to SB623, and PBMC 
function (see Section 15.0).  
6.0 STUDY PARAMETERS AND OBJECTIVES  
The overall objective of the study is to evaluate the safety and efficacy of SB623 cells 
stereotactically implanted in the brains of patients with stable stroke.  
6.1 Parameters  
6.1.1 Safety 
• Adverse events  
• Serious adverse events (SAE)  
• Periodic head MRI scans  
• Serum chemistry, hematology, SB623 antibodies to SB623, cytokines, and PBMC 
function 
6.1.2 Efficacy  
• Clinical Stroke Evaluations : European Stroke Scale (ESS) ,
31 NIH Stroke Scale 
(NIHSS) , Modified Rankin Score (MRS), Fugl -Meyer Score,38 Cognitive Battery (see 
Appendix D, Section 1.0, Table 7).  
• Uptake of fluorodeoxyglucose measured by [CONTACT_28124] (FDG-
PET)  
  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.[ADDRESS_527999] region of brains of patients with stable 
ischemic stroke.  
 6.2.2 Secondary Objectives  
• To estimate clinical improvement of patients primarily with the ESS and secondarily 
with the NIHSS, the MRS, the Fugl-Meyer Score and Cognitive Tests 
• To estimate metabolic improvement in and around the infarct region using FDG- PET 
7.[ADDRESS_528000] stereotactic coordinate frame ( Leksell 
Stereotactic System®, manufactured by [CONTACT_418585]55) is to be applied to the head under local 
anesthesia and mild sedat ion.  Either a head CT scan overlaid on the Baseline MRI or a head  
MRI scan alone is to be performed for stereotactic targeting.  The MRI scans are to use insulated posts an RIF transmitter head, and 1.[ADDRESS_528001] spaced by 5 -6 mm at the target  
One burr-hole craniostomy (1-1.5 cm) is to be fashioned under local anesthesia.  The dura is 
to be opened and a 1.8-mm outer- diameter, [ADDRESS_528002] proximal to the penumbra of the stroke area.  The solid stylet is then to be removed, followed by [CONTACT_418586] a 0.9- mm outer diameter, 19 -cm. long, 20-µL volume Pi[INVESTIGATOR_418549]  (previously qualified for product stability and delivery and provided by [CONTACT_1034]) down to the deepest target point for the first implantation.  A total volume of 100 µL of cell suspension is to be aspi[INVESTIGATOR_38105] a 100-µL syringe through the implant cannula.  The implantation cannula is then to be filled with cell suspension.  Five 20-µL volumes of cells are to be injected slowly (approximately 10 µL/min.) into 5 implantation sites, slowly 
withdrawing the stabilizing needle probe so that the implantations are spaced as equally as possible (intervals of 4 -5 mm) with [ADDRESS_528003] based on the patient’s own neuroanatomy.  This procedure is to be repeated with [ADDRESS_528004]'s head as flat as possible for the next [ADDRESS_528005]- operative 
day (Day 2; see Section 10.5) to insure there are no significant bleeding risks . 
8.[ADDRESS_528006]-stroke, and having a motor neurological deficit 
4. No significant further improvement with physi cal therapy /rehabilitation  (confirmed 
by [CONTACT_418567] ±1 within three weeks prior to enrollment) 
5. Modified Rankin Score of 3 or 4  
6. NIH Stroke Scale score of >7  
7. Two evaluations during prior 3 weeks with no more than  ±1 point change in clinical 
evaluation using the NIH Stroke Scale  
8. Able and willing to undergo computed tomography (CT), magnetic resonance imaging (MRI), and positron-emission tomography (PET) scans of the head 
9. Agree that use of antiplatelet, anti -coagulant, or non- steroidal anti- inflammatory 
drugs to be determined by [CONTACT_418587]  2012 guideline  “Perioperative Management of Antithrombotic Therapy: 
Antithrombotic Therapy and Prevention of Thrombosis, 9
th Edition: Amer ican 
College of Chest Physicians Evidence -Based Clinical Practice Guidelines”,  if 
applicable1, provided that no antiplatelet, anti-coagulant, or non- steroidal anti-
inflammatory drugs are to be restarted after surgery until after the Day 8 MRI is read and determined to be safe to re- start 
10. Normal emotional status; i.e. , no disabling psychological deficits 
11. Ability of patient or legal authorized representative  to understand and sign an 
Informed Consent 
8.[ADDRESS_528007] size >100 cm
3 measured by [CONTACT_9268]  
4. Myocardial infarction within prior 6 mos 
5. Known presence of any malignancy except squamous or basal cell carcinoma of the skin 
6. History of CNS malignancy 
7. History of seizures or current use of antiepi[INVESTIGATOR_7377]  
8. Uncontrolled systemic illness, including, but not limited to: hypertension (systolic >150 mm Hg  or diastolic >95 ); diabetes; renal, hepatic, or cardiac failure  
9. Uncontrolled psychiatric illness, including depression (Hamilton Score >14) 
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  
  
  Page 40 of 85 10. Total bilirubin >1.5 mg/dL  
11. Serum creatinine >1.5 mg/dL  
12. Hemoglobin <10.0 g/dL  
13. Absolute neutrophil count <2000 /mm3 
14. Lymphocytes <800 /mm3 
15. Platelet count <100,000/mm3 
16. Liver disease supported by [CONTACT_42458] (SGOT) or ALT (SGPT) ≥2.5 x institutional upper 
limit of normal 
17. Serum calcium >11.5 mg/dl  
18. International Normalized Ratio of Prothrombin Time (INR) >1.[ADDRESS_528008] values (blood tests, electrocardiogram 
[ECG], chest X -ray); patients with electrocar diographic evidence to suggest a recent 
myocardial infarction, major dysrhythmia, x -ray evidence of infection, atrial 
fibrillation, or congestive heart failure will be excluded  
23. Participation in any other investigational trial within 4 weeks of initial scre ening and 
within 7 weeks of study entry  
24. Botulinum toxin injection, phenol injection, intrathecal baclofen, or any other interventional treatments for spasticity (except bracing and splinting) within the previous [ADDRESS_528009] 6 months of the study  
30. Presence of ser um antibodies to donor SB623 cells with a Luminex value of >1000 
MFI (Maximum Fluorescence Intensity) : HLA Class I (HLA -A*23:PWMV, HLA -
A*68:CGBR; HLA -B*45:FJH, HLA -B*53:KJW; or HLA -Bw4, HLA -Bw6; HLA-
Cw*04:SSWB, HLA -Cw*16:01); or Class II (HLA -DRB1 *13:NGUB , HLA -DRB1 
*16:02; HLA -DQB1*05:CHZY, HLA -DQB1*05:BK; HLA -DQA1*01:DVB, HLA -
DQA1*X, HLA -DRB3,4,5: 3*03:01, HLA -DRB3,4,5: 5*02:02)  
31. Any other condition or situation that the investigator believes may interfere with the safety of the subject or the intent and c onduct of the study  
9.0 INVESTIGATIONAL PLAN  
9.1 Overall Study Design  
This is an open- label study of stereotactic, intracranial injection of SB623 cells (SB623 cells) 
in patients with hemiparesis from stable ischemic stroke who have remained stable during the 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 41 of 85 prior 3 weeks  (as documented by [CONTACT_418588] -3 and - 1).  Three cohorts will 
receive escalating singe doses of SB623, which are to be stereotactically implanted into grey 
or white matter sites adjacent to the infarct region.  One burr -hole cr aniostomy will be 
created, and cells implanted using 3 needle tracks with 5 cell deposits for each track at varying depths.  Cell implantation will be standardized as to volume (20 µL/deposit) and rate (10 µL/min) , with spacing between each implant of appr oximately [ADDRESS_528010] (DSMB).  For the first cohort, a 
single patient will first be dosed, then evaluated over a [ADDRESS_528011] a dose- limiting toxicity attributable to the SB623 cells, then no further patients 
will be dosed in that or other higher -dose cohorts.  Each dose- limiting -toxicity will be 
evaluated by [CONTACT_4318].  The DSMB shall be the final arbitrator for attributions.  
9.2 Duration of Patient Participation 
Two years  (except if there is an unresolved Grade [ADDRESS_528012] possibly related to 
the therapy, in which case the patient will be followed until resolved or reduced to Grade 1) . 
10.[ADDRESS_528013] 
Eval.  
Study Day    -2 to-1 -1 to 1  1 2 8       
Study Week  -3 -1 1 1 1 1 2       
Study Month         End of 1 
and 2  End of 3 
and 4  End 
of 6 End 
of 9 End 
of 12  End 
of 24  
Informed Consent  X3             
Demographics  X             
Inclusion/Exclusion  X  X           
Medical History  X X4 X5 X6          
Medication History  X X4 X5 X6          
Signs & Symptoms  X X4 X5 X6          
Pregnancy Test7 X8  X           
Physical Exam.  X  X         X X 
Vital Signs  X X X    X X X X X X X 
Chest X -Ray and ECG  X             
Hematology (Section 15.3) X X X    X X X X X X X 
Serum Chemistry (Sect.  15.3) X X X    X X X X X X X 
INR X  X           
Occult Malig. (Sect.  10.2.2 ) X             
Lipid Panel (Section 15.3)   X    X X X X X X X 
Cytokines (Section 15.3)   X    X X (mo. 2)  X (mo. 4)  X X X X 
Blood for HLA antibodies  X9             
Head CT      X         
Imaging --Head FDG -PET   X       X  X X 
Imaging --Head MRI  X10  X  X11 X X X X X X X X 
                                                 
1 Only after documentation of stable stroke by [CONTACT_418589] 3 weeks prior to study entry using the NIH Stroke Scale (no more than ±1 point) 
2 Enrollment only after all inclusion and exclusion criteria are verified and the patient qualifies for the study  
3 Prior to any study -related procedures  
4 Only changes since Screen 1  
5 Only changes since Screen 2  
6 Only changes since Baseline  
7 Only for wo men of childbearing potential  
8 Serum β -HCG at Screening; serum or urine β -HCG at Baseline  
[ADDRESS_528014] 
Eval.  
Study Day    -2 to-1 -1 to 1  1 2 8       
Study Week  -3 -1 1 1 1 1 2       
Study Month         End of 1 
and 2  End of 3 
and 4  End 
of 6 End 
of 9 End 
of 12  End 
of 24  
Clinical Stroke Evaluations  X12 X12 X     X X X X X X 
Cognitive Questionn aire   X       X  X X 
Blood for antibodies to 
SB623 and for PBMCs    X    X X (mo. 2) X (mo. 4) X X X X 
Serum Antibod. (see Sect. 
15.6 for assay schedule )              
PBMC Function (see Sect. 
15.7 for assay schedule)               
Adverse Events      X X X X X X X X X 
Concomitant Medications      X X X X X X X X X 
 
                                                 
12 NIHSS and Modified Rankin at Scr. 1 and only NIHSS at Scr. 2  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  
  
  Page 44 of 85 10.2 Pre-study Evaluation and Baseline ( Pre-Screen, Scr.  1, Week -3 and Scr. 2, 
Week  -1) 
The following will be done prior to performing any study- specific procedures:  
• Informed Consent Signed: study- related details will be carefully discussed with the 
patient.  The patient will sign an Informed Consent Form approved by [CONTACT_418590].  
10.2.1 Pre-Screen (Optional)  
• Blood sample for determination of presence of antibodies to donor SB623 cells with a 
Luminex value of >1000 MFI (Maximum Fluorescence Intensity) : HLA Class I 
(HLA -A*23:PWMV, HLA-A*68:CGBR; HLA-B*45:FJH, HLA-B*53:KJW; or 
HLA -Bw4, HLA- Bw6; HLA -Cw*04:SSWB, HLA-Cw*16:01); or Class II ( HLA -
DRB1 *13:NGUB, HLA-DRB1 *16:02; HLA-DQB1*05:CHZY, HLA-
DQB1*05:BK; HLA-DQA1*01:DVB, HLA-DQA1*X, HLA-DRB3,4,5: 3*03:01, HLA -DRB3,4,5: 5*02:02) 
• Head MRI  
10.2.2 Scr. 1, Week -3 
• Inclusion/Exclusion Criteria  
• Demographics 
• Medical History  
• Medication History  
• Signs & S ymptoms  
• Pregnancy Test (serum β -hCG)  
• Physical Exam.  
• Vital Signs  Including Weight 
• Chest X -Ray and ECG 
• Hematology  (Section 15.3)  
• Serum Chemistry  (Section 15.3)  
• INR 
• Determination of occult malignancy by [CONTACT_418591] (hemocult test), finding on chest x-ray, carcinoembryonic antigen, prostate- specific antigen (males onl y), 
cancer antigen 125  (females only) , α-fetoprotein, and β -hCG 
• Blood sample for determination of presence of serum antibodies to donor SB623 cells 
with a Luminex value of >1000 MFI (Maximum Fluorescence Intensity) : HLA Class 
I (HLA -A*23:PWMV, HLA -A*68:CGBR; HLA-B*45:FJH, HLA-B*53:KJW; or 
HLA -Bw4, HLA- Bw6; HLA -Cw*04:SSWB, HLA-Cw*16:01); or Class II (HLA-
DRB1 *13:NGUB, HLA-DRB1 *16:02; HLA-DQB1*05:CHZY, HLA-
DQB1*05:BK; HLA-DQA1*01:DVB, HLA-DQA1*X, HLA-DRB3,4,5: 3*03:01, HLA -DRB3,4,5: 5*02:02) 
• Imaging ( head MRI : only if not done at a pre- screen visit ) 
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 45 of 85 • Clinical Stroke Evaluations  (NIHSS and Modified Rankin only) 
10.2.3 Scr. 2, Week -1 (±2 Days)  
The following will be performed: 
• Medical History (only changes since Scr. 1) 
• Medication History (only changes since Scr. 1) 
• Signs & Symptoms (only changes since Scr. 1) 
• Vital Signs  
• Hematology  (Section 15.3)  
• Serum Chemistry  (Section 15.3) 
• Clinical Stroke Evaluations  (NIHSS only) 
10.3 Baseline and Enrollment (Days -2 to 1 , not including weekends ) 
10.3.1 Baseline ( Weekday -1 to -2 ) 
The following will be performed at Baseline:  
• Inclusion/Exclusion 
• Medical History (only changes since Screen 2)  
• Medication History (only changes since Screen 2) 
• Signs & Symptoms (only changes since Screen 2) 
• Pregnancy Test (serum or urine β -hCG)  
• Physical Exam.  
• Vital Signs  
• Hematology  (Section 15.3) 
• Serum Chemistry  (Section 15.3) 
• INR 
• Lipid Panel (Section 15.3) 
• Cytokines (Section 15.3) 
• Imaging (head MRI & FDG -PET)  
• Clinical Stroke Evaluations  
• Cognitive Questionnaire (Section 23.0, Table 7) 
• Blood for antibodies to SB623 and peripheral blood mononuclear cells (PBMC) 
function assays and for storage of PBMCs (Section 15.7) 
• Luminex assay for antibodies to SB623 
 
10.3.2 Enrollment (Days -1 or 1) 
Enrollment can only occur after performing all assessments and verifying that the patient meets the inclusion and exclusion c riteria for the study.  
  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  
  
  Page 46 of 85 10.4 Cell Administration  (Day 1) 
Prior to any procedures, the patient will be queried on the use of any changes in medication 
since Baseline.  
Prior to cell implantation, either a head CT overlaid with the Baseline head MRI or a head MRI  alone will be done to determine the exact locations for the implants.  
Using the procedures in Section 6.0, surgical and implantation Procedures  and Section 10.4, 
Preparation and Administration, one burr hole will be made in the skull of the patient in a 
location that will allow ready access to the infarct region.  Cells will be implanted using 3 needle tracks with 5 cell deposits for each track at varying depths.  Cel l implantation will be 
standardized as to volume (20 µL/deposit) and rate (10 µL /min), with spacing between each implant of approximately 5 -6 mm. 
After cell implantation, the following will be performed: 
• Imaging (head CT only) 
• Adverse Events  
• Concomitant m edications  
10.5 Follow-Up Period (Study Day 2) 
The following will be performed: 
• Adverse Events  
• Concomitant Medications (see Section 12.0) 
• Head MRI  (MRI must be read bef ore re -starting any antiplatelet, anticoagulant, or 
non-steroidal anti- inflammatory agents)  
10.6 Follow-Up Period (Study Day 8) 
The following will be performed: 
• Vital Signs  
• Hematology  (Section 15.3) 
• Serum Chemistry  (Section 15.3) 
• Lipid Panel (Section 15.3) 
• Cytokines (Section 15.3) 
• Head MRI  
• Blood for antibodies to SB623 and peripheral blood mononuclear cells (PBMC) 
function assays and for storage of PBMCs (Section 15.7) 
• Luminex assay for antibodies to SB623 and PBMC function assay 
• Adverse Events  
• Concomitant Medic ations (see Section 12.0) 
  
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 47 of 85 10.7 Follow-Up Period (End of Months 1, 2, 3, 4 ± 5 Days)  
• Vital Signs  
• Hematology  (Section 15.3)  
• Serum Chemistry  (Section 15.3) 
• Lipid Panel (Section 15.3) 
• Plasma Cytokines (months 2, 4 only) (Section 15.3) 
• Imaging (head MRI)  
• Clinical Stroke Evaluations  
• Blood for antibodies to SB623 and peripheral blood mononuclear cells (PBMC) 
function assays and for storage of P BMCs  (Months 2, 4 only) (Section 15.7) 
• Luminex assay for antibodies to SB623 and PBMC function assay (Months 2, 4 only) 
• Adverse Events  
• Concomitant Medications (see Section 12.0) 
10.8 Follow- Up Period (End of Month 6  ±7 Days) 
• Vital Signs  
• Hematology  (Section 15.3) 
• Serum Chemistry  (Section 15.3)  
• Lipid Panel ( Section 15.3)  
• Plasma Cytokines (Section 15.3)  
• Imaging (head MRI & PET)  
• Clinical Stroke Evaluations  
• Cognitive Questionnaire (Section 23.0, Table 7)  
• Blood for antibodies to SB623 and peripheral blood mononuclear cells (PBMC) function assays and for storage of PBMCs  (Section 15.7)  
• Luminex assay for antibodies to SB623 and PBMC function assay 
• Adverse Events  
• Concomitant Medications (see Section 12.0)  
10.9 Follow-Up Period (Months 9, 12 ±7 Days) 
• Physical Exam. (Month 12 only) 
• Vital Signs  (Including Weight for Mo. 12 only) 
• Hematology  (Section 15.3)  
• Serum Chemistry  (Section 15.3)  
• Lipid Panel 
• Plasma Cytokines (Section 15.3)  
• Imaging --Head MRI  
• Imaging —FDG PET (mo. 12 only) 
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  
  
  Page 48 of 85 • Clinical Stroke Evaluations  
• Cognitive Questionnaire (Month 12 only) (Section 23.0, Table 7) 
• Blood for antibodies to SB623 and peripheral blood mononuclear cells (PBMC) 
function assays and for storage of PBMCs (Month 12 only) 
• Luminex assay for antibodies to SB623 and PBMC function assay 
• Adverse Events  
• Concomitant Medications (see Section 12.0) 
10.[ADDRESS_528015] Evaluation (End of Month 24 ±14 Days or Early Withdrawal) 
• Physical Exam.  
• Vital Signs  Including Weight 
• Hematology  (Section 15.3) 
• Serum Chemistry  (Section 15.3) 
• Lipid Panel 
• Plasma Cytokines (Section 15.3) 
• Imaging (head MRI & PET)  
• Clinical Stroke Evaluations  
• Cognitive Questionnaire (Section 23.0, Table 7) 
• Blood for antibodies to SB623 and peripheral blood mononuclear cells (PBMC) 
function assays and for storage of PBMCs  (Section 15.7) 
• Luminex assay for antibodies to SB623 and PBMC function assay 
• Adverse Events  
• Concomitant Medications (see Section 12.0) 
11.0 DESCRIPTION OF STUDY TREATMENT 
11.1 Study Drug Description 
SB623 cells are provided as a 1 -mL sterile cell suspension, containing ≥5 X 106 cells/mL, 
cryopreserved in CryoStore™ freezing media. 
11.2 Study Drug Packaging  
Individual 1.5- mL Nalgene™ cryo vials.  
11.3 Study Drug Shipment and Storage  
The cryovials containing the frozen cell suspensions are shipped in a dry nitrogen shipper 
and should be stored in the vapor phase within the shippi[INVESTIGATOR_418550] a GMP -compliant liquid nitrogen container. 
The Sponsor will arrange for Study Drug to be shipped to the clinical site. 
 
  
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 49 of 85 11.4 Preparation and Administration 
Details for preparation of the cell suspension for administration will be provided by [CONTACT_429].  Cl inical sites will be provided necessary materials for reconstitution of the cells 
and will be trained by [CONTACT_1034].  The cryopreserved cells will be thawed, washed, centrifuged, and re-suspended in Plasma- Lyte A at varying concentrations (see Section 4.1) 
for administration to the patient within approximately [ADDRESS_528016] cell wash to insure continued sterility.  If the endotoxin level is > 5 EU/mL or the gram stain is positive, implantation will not occur.  If the sterility test is positive, an investigation will be conducted to determine the source of the contamination.  In addition, identification of the pathogen and sensitivity will be done and the patient treated with an appropriate antibiotic.  In this event, the patient will be followed closely for adverse events associated with a possible infection and response to antimicrobial therapy, including frequent clinic visits until any infection is cleared.  
This Investigational Product may not be used for any purpose other than this clinical study. 
11.5 Study Drug Accountability Procedures  
The Investigator will be responsible for maintaining inventory and accounting for all Study 
Drug received from the Sponsor on a drug accountability log.  After reconciliation has been completed, all Study Drug vials received by [CONTACT_737] (used and unused) will be collected, and the used vials destroyed at the site under supervision of the monitor per institutional standard operating procedure.  Unopened vials will be kept frozen until returned to the Sponsor. 
12.[ADDRESS_528017] Study 
Drug will be documented.  Documentation (through month 9 only) will include changes from the prior visit, start and stop dates, dose, and reasons for the medication use. 
Investigational drugs or devices for any other indication are not allowed during the study. 
13.0 STUDY WITHDRAWAL/TERMINATION 
13.[ADDRESS_528018], or significant non-compliance to the protocol or to Good Clinical Practices (GCPs).  Should patient enrollment be unsatisfactory, or data recording be inaccurate and/or incomplete, the Sponsor may terminate the study and remove all study ma terials from the study site.  
  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  
  
  Page 50 of 85 13.3 Patient Discontinuation  
Patients will be free to discontinue from the study at any time without giving a reason(s).  
Patients will be considered discontinued from the study in the event of any of the following reasons:  
• Withdr awal of the patient’s consent for any reason  
• Investigator’s discretion due to patient’s medical condition 
If patient withdrawal occurs during the study period, the Last Evaluation visit should be performed, whenever possible, at the time of patient withdr awal or as soon as possible (see 
Section 10.8).  The Investigator should continue to evaluate the medical condition of any patient who has withdrawn for [ADDRESS_528019] to review by [CONTACT_418592].  
15.0 CLINICAL AND LABORATORY EVALUATIONS AND PROCEDURES  
15.1 Medical History  
Medical history will include significant medical conditions and surgical history, medications taken within 2 weeks prior to signing the Informed Consent, and signs and symptoms occurring within 3 weeks after signing the Informed Consent. 
15.2 Physical Examinati on and Vital Signs  
A complete physical examination will be performed (including a genital/rectal exam if 
clinically indicated).  
Vital signs will include oral temperature, blood pressure at rest, heart rate, and respi[INVESTIGATOR_697] (and Weight for Weeks -3, and Mos. 12, 24). 
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 51 of 85 15.3 Safety Laboratory 
All safety laboratory evaluations will be conducted at the laboratories located at or associated 
with the clinical site.  At every sampling time point, approximately 5 mL of blood will be drawn for each of the hematology and serum chemistry panels. 
The following laboratory evaluations will be performed: 
• Hematology Panel: hematocrit, hemoglobin, WBC, platelet count, lymphocyte count, 
neutrophil count 
• Serum Chemistry Panel: sodium, chloride, calcium, potassium, magnesium, bicarbonate, lactate, C -reactive protein, glucose, creatinine, BUN, AST, ALT, 
alkaline phosphatase, and total bilirubin 
• Lipid Panel: total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides 
• Cytokines: Plasma TNF -α, Plasma IL-6, and Plasma  IFN-γ 
• INR 
15.[ADDRESS_528020]: Serum or urine β-hCG  
• Serum β-hCG at Screening 1 (using same blood draw as for serum chemistry) 
• Urine β -hCG at Baseline 
15.5 Antibodies to HLA Antigens on SB623  
• A serum sample, taken at initial screening  (and opti onally at a Pre- Screening visit) 
will be used to determine the presence of antibodies to donor SB623 cells with a 
Luminex value of >1000 MFI (Maximum Fluorescence Intensity) : HLA Class I 
(HLA -A*23:PWMV, HLA-A*68:CGBR; HLA-B*45:FJH, HLA-B*53:KJW; or 
HLA -Bw4 , HLA -Bw6; HLA -Cw*04:SSWB, HLA-Cw*16:01); or Class II (HLA-
DRB1 *13:NGUB, HLA-DRB1 *16:02; HLA-DQB1*05:CHZY, HLA-DQB1*05:BK; HLA-DQA1*01:DVB, HLA-DQA1*X, HLA-DRB3,4,5: 3*03:01, HLA -DRB3,4,5: 5*02:02) 
15.6 Serum Antibodies to SB623 
Serum antibody measurements will be made to monitor a possible humoral- mediated 
immune response.  Blood samples (approximately 10 mL) will also be taken at the intervals indicated in Table 4 for m easurements of serum antibodies to SB623 using the Luminex 
assay .  Assays may be done bimonthly on pooled samples. 
15.7 PBMC  Function  
PBMC function will be evaluated to monitor any possible cell-mediated immune responses, including inflammation.  
Blood samples ( approximately 20 mL) will also be taken at the intervals indicated in Table 4.  
PBMCs from Baseline Samples will be aliquoted into approximately [ADDRESS_528021] 600,000 cells per tube, then kept frozen in vapor phase of liquid nitrogen until needed as controls for subsequent time-point assays .  For all other time points, PBMCs will be isolated 
and the sample split into multiple  vials of equal portions (A and B) containing at least  
600,000 cells each, then similarly frozen until time to assay PBMC function.   PBMC 
function during the study will be determined on the A portions by [CONTACT_418593], Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  
  
  Page 52 of 85 PMA/ionomycin/ SB623, evaluating any changes from baseline in cytokine secretion.  These 
evaluations on batched  samples of PBMCs will be approximately at bimonthly intervals 
during the first [ADDRESS_528022] year, then at 2 years. 
B portions of PBMCs will be stored  in the vapor phase of liquid nitrogen until requested by 
[CONTACT_418594]. 
15.8 Clinical Stroke Evaluations 
15.8.1 European Stroke Scale (ESS) 
Specific information on scoring using the ESS31 can be found in the publicatin. 
15.8.2 National Institute of Health (NIH) Stroke Scale 
Specific information on scoring using the NIH Stroke Scale56 can be found in the 
publication. 
15.8.3 Modified Rankin Scale (MRS) 
Specific information on scoring using the MRS34,[ADDRESS_528023] will be determined by [CONTACT_2363] 
18F-fluorodeoxyglucose uptake measured by [CONTACT_28124] (PET). 
16.0 ADVERSE EVENTS  
16.1 General Information 
An adverse event  (AE) is any untoward medical occurrence in a patient or clini cal 
investigation subject administered a pharmaceutical product and that does not necessarily 
have a causal relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product.  This includes any side effects, injury, toxicity, or sensitivity reaction, and may include a single symptom or sign, a set of related symptoms or signs, or a disease.  An adverse event is also any laboratory abnormality judged to be clinically significant by [CONTACT_91564]- investigator(s) that 
worsened compared to Baseline.  
Throughout the course of the study, every effort should be made to remain alert to possible adverse experiences.  Patients should be encouraged to report adverse events spontaneously or in response to general, non-directed questioning. 
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 53 of 85 With the occurrence of an adverse event, the primary concern is the safety of the patient.  If 
necessary, appropriate medical intervention should be provided, and the investigational drug 
discontinued. 
An AE does not  include:  
• Medical or surgical procedures ( e.g., surgery, endoscopy, tooth extraction, 
transfusion); the condition that leads to the procedure is an adverse event  
• Pre-existing diseases or conditions present or detected at the start of the study that do 
not worsen in severity or frequency  
• Situations where an untoward medical occurrence has not occurred ( e.g., 
hospi[INVESTIGATOR_418551], social and/or convenience admissions)  
• Overdose of either Study Drug or concomitant medication without any signs or 
symptoms  
A Serious Adverse Event (SAE)  is any adverse event that results in any of the following:  
• death,  
• life-threatening event,  
• hospi[INVESTIGATOR_318], 
• a persistent or significant disability/incapacity,  
• congenital anomaly/birth defect, or  
• an event that may require intervention to prevent any one of the other outcomes listed above (based on medical judgme nt) 
An Unexpected Adverse Event  is any AE that is not identified in nature, severity, or 
frequency in the current Investigator’s Drug Brochure or product information.  For this study, an unexpected adverse event also includes neurological deterioration, pr ocedural 
complications, seizures, benign and malignant tumors and pregnancy, and will be submitted as expedited reports.  
An Unexpected Adverse Drug Reaction  (ADR) is an adverse reaction, the nature or 
severity of which is not consistent with the applicable  product information ( e.g., 
Investigator’s Brochure for an unapproved investigational medicinal product).  All noxious and unintended responses to a medicinal product related to any dose should be considered ADRs.  All serious and unexpected ADRs will have  expedited reporting to the FDA.  
16.[ADDRESS_528024] dose of Study Drug and ends 24 weeks after the administration of SB623.  
All AEs (both serious and non- serious)  must be followed until resolution or until a stable 
clinical endpoint is reached.  All measures required for AE management and the ultimate outcome of the AE must be recorded in the source document and reported to the Sponsor. 
  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.[ADDRESS_528025] terminology provided by [CONTACT_418595] 
(e.g., CRO), such as COSTART terminology.  
The WHO (World Health Organization) Standard Toxicity Criteria (STC) will be used to assist in categorizing and grading adverse events.  A copy of the WHO STC will be provided in the study documents.  Whenever possible, a diagnosis should be given when signs and symptoms are due to common etiology ( e.g., cough, runny nose, sneezing, sore throat, and 
head congestion should be reported as “upper respi[INVESTIGATOR_4416]”).  
16.[ADDRESS_528026] his/her opi[INVESTIGATOR_418552].  Table 5 below provides guidance for assigning relationship to Study Drug.  
Table 5 Relationship of A dverse Event to the Administration of the Study Drug  
Unrelated  There is not a temporal relationship to study drug administration (e.g., too early, 
too late, or study drug not taken), or there is a reasonable causal relationship 
between another drug, concurrent disease, or circumstance and the AE.  
Unlikely  There is a temporal relationship to study drug administration, but there is not a 
reasonable causal relationship between the study drug and the AE ( i.e., the AE 
is doubtfully related to study drug)  
Possibly  There is a reasonable causal relationship between the study drug and the AE.  
Information related to withdrawal of study drug is lacking or unclear  
Probably  There is a reasonable causal relationship between the study drug and the AE.  
The event  responds to withdrawal of study drug.  Re -challenge is not required  
Definitely  There is a reasonable causal relationship between the study drug and the AE.  
The event responds to withdrawal of study drug, and recurs with re -challenge, 
when clinically fe asible  
 
16.5 Reporting Serious or Unexpected AEs  
Any Serious Adverse Event, including death that occurs during this study (from the first dose 
of Study Drug up to and including [ADDRESS_528027] dose of Study Drug), whether or not the event is considered to be related to the study treatment, mus t be reported 
immediately (within 24 hours after the site becomes aware of the event)  to the Principal 
Monitor. 
The contact [CONTACT_144613]:  
Ernest Yankee, Ph.D.  
Phone: 650- 625-8965 ext 44 
Cell: 650 -892-4448 
Email: ernest.yanke e@san -bio.com  
 
 
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.[ADDRESS_528028] of concomitant medications, relationship of S tudy Drug to SAE, 
autopsy report (if applicable), and any other relevant information such as medical history, hospi[INVESTIGATOR_44458], etc.  The report should be as complete as possible without delaying Sponsor notification. 
An SAE Report should be prepared containing as much available information concerning the 
event as possible so that a written report can be filed with the appropriate regulatory authorities.  Any SAE follow -up information requested by [CONTACT_57756]’s 
designee should be pr ovided in a timely manner.  
Upon receipt of notification of any Serious Adverse Event, the Sponsor will immediately conduct an evaluation of the event and take action indicated by [CONTACT_418596].  This may include notification of the FDA, other Investigators, IRBs and/or the suspension or termination of the study.  The Investigator is required to report Serious Adverse Events and Unexpected Adverse Events to the local Ethics Committee (EC) or Institutional Review Board (IRB) in accordance with  the EC/IRB by[CONTACT_28769].  
All additional follow -up evaluations of the SAE must be reported to the Sponsor.  These data 
should be faxed to the Principal Monitor at 650- 625-8472 as soon as they are available.  
16.6 Follow -up of Adverse Events  
All AEs (both serious and non- serious) should be followed until resolution or until a stable 
clinical endpoint is reached.  All measures required for AE management and the ultimate outcome of the AE must be recorded in the source document and reported to the Sponsor. 
17.[ADDRESS_528029] (DSMB) will continuously evaluate toxicity and 
mortality rates, and recommend appropriate actions, according to the DSMB Charter.  
18.0 STATISTICAL METHODS  
18.1 Overview of Analysis  
18.1.1 Safety Parameters  
• Adverse events related to the surgical procedure  
• SB623- related adverse events  
• Adverse changes imaged by [CONTACT_418569] (edema, adverse anatomical changes)  
• Serious adverse events (SAEs)  
• Serum chemistry and hematology  
  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  
  
  Page 56 of 85 18.1.2 Efficacy Parameters  
• Clinical improvement of stroke symptoms using the European Stroke Scale, the NIH 
Stroke Scale,  and the Modified Rankin Scale; improvement in motor functions using 
the Fugl -Meyer scale, and improvement in cognitive status using a test battery 
(including Rey Complex Figure Test; se e Appendix D ) 
• Increase in fluorodeoxyglucose (FDG) uptake measured by [CONTACT_10052] 
18.1.3 Efficacy Objectives  
Primary:  
• To evaluate clinical (ESS) and radiographic (FDG -PET) response to 3 dose 
levels of intracranial administration of SB623 cells at 6 months 
Secondary : 
• To evaluate clinical ( NIHSS, MRS, Fugl-Meyer, Cognitive Tests) response to 3 
dose levels of intracranial administration  of SB623 cells at 6 months 
• To evaluate clinical (ESS, NIHSS ), MRS, and Fugl -Meyer response to 3 dose 
levels of intracranial administration of SB623 cells at 1, 2, 3, 4, 9, 12, and 24 
months; also to evaluate changes from Baseline in cognitive function at 6, 12, and 24 mos., and changes from Baseline in radiographic (DFG- PET) responses at 
6, 12, and 24 mos. 
18.2 Patients to be Included in the Analyses  
18.2.1 Efficacy Population 
The intent- to-treat (ITT) population will include all enrolled patients, including those who 
were discontinued from the study or withdrawn for any reason.  The Evaluable population will be defined in the Statistical A nalysis Plan.  
18.2.[ADDRESS_528030] unless otherwise specified in the Statistical Analysis Plan.  
18.3.2 Secondary Analyses 
The secondary analyses will be pooled analyses of changes from Baseline at 1, 2, 3, 4, 6, 9, 12, and 24 months for all patients for ESS, NIHSS, MRS , and Fugl -Meyer .  Evaluation of 
changes from Baseline for Cognitive Tests, and FDG- PET parameters  will be done at months 
6, 12, and 24.  In addition, possible dose- response will be determined.  Statistics will be done 
as for the Primary Analysis.  
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 57 of 85 18.4 Analysis of Safety 
Adverse events, clinical laboratory data, and vital signs will be analyzed to evaluate the 
safety of SB623 for all patients in the Safety population through 2 years after the dose of Study Drug. 
A tre atment -emergent adverse event will be defined as any event not present prior to the 
initiation of treatment or any event already present that worsens in either intensity or 
frequency following exposure to study treatment.  
All adverse event data will be lis ted per patient including severity, relationship to Study 
Drug, and action taken.  Frequency within each treatment group of each type of adverse event will be summarized using an acceptable coding dictionary.  
Laboratory data and vital signs will be listed by [CONTACT_4676].  Laboratory data values above and below normal ranges which are considered clinically significant will be indicated on the listing.  Descriptive statistics will be displayed for each laboratory parameter and vital sign assessment at each time p oint.  The mean change from baseline in each of these continuous 
variables will also be described.   
18.5 Determination of Sample Size  
The sample size of 6 patients per cohort was determined based on safety considerations.  Based on the animal safety studies, n o dose -limiting toxicity is anticipated.  However, if the 
true rate is 40%, a sample size of 6 patients per cohort would result in a < 5% chance of missing a dose -limiting toxicity.  
18.6 Deviations from the Protocol Analysis Plan  
Any deviations from the origina l planned analysis as described in the protocol will be 
detailed in the final integrated clinical report with an explanation of the alternative methods employed.  
19.0 ADMINISTRATION OF TH E STUDY 
19.1 Regulatory Considerations  
This study will be conducted in compliance with the protocol, ICH Good Clinical Practice Guidelines (GCPs), and the applicable local regulatory requirements.  This study will be conducted in accordance with the ethical principles that originate in the Declaration of Helsinki and ICH Guidelines f or Good Clinical Practices (GCPs).  
Study protocols and Informed Consent Forms will be approved by [CONTACT_418597] (and governmental authorities, as needed) prior to initiation of the study at a particular site .  All patients will sign an Informed Consent Form 
prior to any study -specific procedures.  Performance during the study will be routinely 
monitored by a study monitor selected by [CONTACT_1034]. 
19.2 Independent Ethics Committee (EC)/Institutional Review Board (I RB) 
The Investigator must submit the final protocol and proposed informed consent document to 
an Independent Ethics Committee (EC) or Institutional Review Board (IRB) that complies with the ICH Guideline for Good Clinical Practice.  The EC/IRB will provide the  
Investigator with a written decision regarding the conduct of the study at that site and a copy 
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.[ADDRESS_528031] Manager.  The study will not be initiated 
and patients will not be enrolled until the appropriate documentation of EC/IRB approval of the study protocol and the informed consent has been received. 
Substantive modifications to the protocol will be submitted to the EC/IRB for approval.  
These modifications may be implemented only after EC/IRB written approval has be en 
received and forwarded to the Project Manager.  Administrative changes to the protocol such as a change that has no effect on the conduct of the study or risk to the patient should be submitted to the EC/IRB for review, but formal approval is not requir ed. 
The Investigator must also submit any other written information that will be given to the study patients as well as any advertisements for patient recruitment, if used, to the EC/IRB for approval prior to implementing these documents. 
The Investigator will make appropriate and timely reports to the EC/IRB as required by 
[CONTACT_418598]/IRB policy.  In addition to progress reports, all 
known information regarding serious adverse events, whether observed at their clinical site or at another site participating in a clinical investigation with the Study Drug, will be reported to the EC/IRB.  It is the Sponsor and/or its designee’s responsibility to inform the Investigator of serious adverse events observed at other investigational si tes. 
It is the Investigator's obligation to provide the Sponsor and/or its designees with copi[INVESTIGATOR_120882] -related correspondence with the EC/IRB in a timely fashion and to retain originals 
in a file.  This EC/IRB correspondence file will be made available as requested to appropriate designees for monitoring or quality assurance review and to governmental regulatory representatives during site audits.  
19.[ADDRESS_528032] be approved by [CONTACT_418599]/IRB and by [CONTACT_1034]. 
The patient (or surrogate) and the individual explaining the study will sign the current 
EC/IRB-approved version of the consent form.  A copy of the signed consent form will be given to the patient.  The date tha t consent was obtained will be recorded on the case report 
form as well as in the patient's chart.  
A copy of the EC/IRB-approved version of the consent form will be provided to the Sponsor.  Original signed consent form must be maintained at the site and be made available for inspection, as appropriate. 
A sample consent form is provided in Appendix A . 
19.[ADDRESS_528033] 
be recorded as a protocol deviation and be explained in detail as it occurs and/or is detected. 
19.[ADDRESS_528034] be signed and dated by [CONTACT_418600].  The Sponsor will submit protocol modifications to Regulatory Agencies as required.  The Investigator is responsible for noti fying the EC/IRB of changes.  Substantive changes will 
require EC/IRB approval, such as changes in experimental procedures that affect patient safety, changes in dosage or study treatment, changes in assessment parameters, or changes in patient eligibility  criteria.  The EC/IRB may require the Informed Consent Form to be 
altered in the event of protocol changes or new safety information. 
In situations requiring a departure from the protocol, the Investigator or other physician in 
attendance will contact [CONTACT_418601].  If possible, this contact [CONTACT_418602].  In all cases, contact [CONTACT_418603].  The CRF and source document must describe any departure from the protocol and the circumstances. 
19.6 Data Collection 
Patient screening/enrollment will be documented in a study -specific log at the study site.  
This log will capture the following information: patient number, initials, patient personal 
identification number or medical record number, date of screen/enrollment, reason for not enrolling (if applicable), and any comments. 
A CRF (Case Report Form) will be provided for each study patient.  Data collected through 
the completion of experimental procedures required by [CONTACT_418604]'s chart as source documentation.  This data will then be transcribed onto the CRF. 
All required study data, including results of an autopsy if the patient dies during the study, 
will be entered into the Case Report Forms (CRFs) provided by [CONTACT_1034].  All information in the CRFs must be supported by [CONTACT_418605]’s medical records.  All medical records, laboratory printouts, notes made by [CONTACT_099], and other materials such as x- rays 
will be considered source data and must be available for inspection by [CONTACT_1052]/or delegates, or governmental representatives.  
All entries to the CRF mus t be made in indelible black ink.  All corrections must be made by 
[CONTACT_740] a single line through the error and entering the correct data as close as possible to the original entry without obscuring data.  The correction must be initialed and dated by [CONTACT_36324].  The Investigator remains responsible for the accuracy and adequacy of all data entered on CRFs. 
Data will be monitored as described in  Section 19.8.  Under direction of the clinical monitor, 
CRFs will be pulled and further processed for data entry and analysis.  A copy of each CRF 
page must remain at the investigative site in the appropriate patient's CRF binder.  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.[ADDRESS_528035] contain the documents 
identified in  Appendix B, including a signed Investigator Agreement.  The Sponsor, or its 
designee, will provide a Study Binder to the site. 
According to U.S. Federal Regulations (21 CFR 312), all records relat ed to this clinical trial 
must be retained by [CONTACT_12103] [ADDRESS_528036] be retained include, but are not necessarily limited to: patient charts, case report forms, product disposition records, essential documents identified in Appendix B, and study reports.  
19.8 Monitoring, Auditing, Inspecting  
The Sponsor or designee ( e.g., clinical research organization [CRO]) will assure the accuracy 
of data, the selection of qualified Investigators, appropriate study centers and review protocol procedures with the Investigators and associated pers onnel prior to the study and during 
periodic monitoring visits.  The Sponsor or a designee will review CRFs for accuracy and completeness during on- site monitoring visits and after their return from the clinical site.  
Discrepancies will be resolved with t he Investigator as appropriate.  
The Sponsor or its designees will monitor the study using the following methods:  
• frequent telephone contacts  
• periodic site visits  
• review of original patient records, case report forms, drug accountability and 
storage, and general study documentation 
So that the study may be adequately monitored, the Investigator will cooperate in providing 
the Sponsor’s designees with all study documents (e.g., patient charts and study files) and responding to inquiries that may arise as a result of the document review.  
Review of these documents will usually occur during a routine monitoring visit, but may also be required during a visit by a quality assurance auditor.  The Investigator will also provide access to these records to regulatory  representatives if and when requested.  The Sponsor 
reserves the right to terminate the study site if access to source documentation of work performed in this study is denied to the Sponsor or regulatory representatives. 
19.[ADDRESS_528037] be maintained.  Patients will be 
identified by [CONTACT_418606].  Documents that are not submitted to the Sponsor and 
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 61 of 85 that identify the patient ( e.g., signed informed consent; source documents/charts) will be 
made available to the Sponsor or regulatory authorities for inspections, but will be 
maintained in confidence. 
All study related information provided by [CONTACT_51883], including but not limited to the active study agent identity, the investigator's brochure, the study protocol, verbal and written communication, case report forms, assay methods and scientific data, will be considered confidential.  In addition, all information developed during the conduct of the clinical investigation of the study agent is also considered confidential.  Neither the Investigator nor any of his/her employees or agents shall disclose or use this information for any purpose other than the performance of the clinical study.  Such information shall remain the confidential and proprietary property of the Sponsor, and disclosure to others will be limited to other physicians who are conducting studies with the same active study agent, the Ethics Committee/IRB and the applicable regulatory authorities except by [CONTACT_418607].  At such time that information becomes widely and publicly available through no fault of the Investigator, the obligation of nondisclosure toward that particular information will cease.  
19.[ADDRESS_528038] submit a copy of the desired presentation (oral or written) or publication manuscript to the Sponsor.  This review period may be shortened upon mutual consent where circumstances require expeditious review.  The Sponsor reserves the right to suggest modification of any publication, presentation or use by [CONTACT_418608] a patent application, an existing patent, or other proprietary rights.  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  
  
  Page 62 of 85 20.0 APPENDIX A:  SAMPLE INFORMED CONS ENT  
(Final v ersion to follow institutional standards)  
 
 Patient 
Initials  ____ ____ ____  
 
   
 Date  ___ / ___ / ___  
 
 
AUTHORIZATION TO PARTICIPATE IN A RESEARCH PROJECT  
TITLE OF STUDY:  
A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in 
Patients with Stable Ischemic Stroke  
 
SPONSOR:     SanBio, Inc.  
[ADDRESS_528039].  
     Mountain View, CA  [ZIP_CODE] 
 
PROTOCOL NO.:    SB-STR01  
INVESTIGATOR:     
TELEPHONE:     
STUDY SITE LOCATION:    
INTRODUCTION:  
You are being invited to take part in a research study that will last approximately 24 months for you.  Approximately 18 patients  will participate in this study.  It is important that you 
read and understand several general principles that apply to all study participants:  
1. Taking part in the study is entirely voluntary  
2. You do not have to be in any research study offered to you by [CONTACT_4904].  When you are deciding if you should join the study, you may want to talk with someone not part of the study about your questions and feelings about joining.  This could be a family member, friend, or another health provider  
3. Personal benefit to you (improvement in your stroke symptoms) may or may not result from taking part in the study.  Knowledge will be gained from your participation that may ben efit other patients.  
4. You may withdraw from the study at any time without penalty or loss of any benefits to which you are otherwise entitled. 
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.[ADDRESS_528040] should be discussed with the staff members.  They will explain it to you.  
NOTE: If you are not completely truthful with your study doctor regarding your h ealth 
history, you may harm yourself by [CONTACT_4907].  
THE NATURE AND PURPOSE OF THIS STUDY:  
You have been diagnosed with stable ischemic stroke, and have had physical therapy for your stroke -related conditions.  Your stroke was caused by a blood clot in a blood vessel in 
your brain and this happened at least [ADDRESS_528041] that you wil l be using is an investigational drug (not approved by [CONTACT_418609]).  
EXPLANATION OF PROCEDURES TO BE FOLLOWED:  
After you sign the consent form and before you begin treatment, you will be asked questions 
about your medical history, medications you are taking, and how you feel.  You will also have a complete physical examination.  The doctor will check your pulse, blood pressure, 
respi[INVESTIGATOR_7146].  
Approximately 25 mL (a little less than one ounce or two tables poons) of blood will be 
drawn and a urine sample will be requested for monitoring your health status and to confirm that you are eligible to participate in the study.  If you are a woman capable of bearing a child, the blood sample will also be used for a pregnancy test.  
You will be evaluated for your stroke symptoms by a variety of methods, such as asking you questions and requesting you to make certain movements while you are being videotaped.  This will be done twice prior to implantation of the SB623 ce lls, over a three week period.  
This is to confirm that your stroke symptoms are stable.  
You will also be asked to undergo magnetic resonance imaging (MRI)  of your head at your 
first screening visit.  The purpose of the MRI is to determine the precise location and size of 
your stroke and to ensure there are no other abnormalities.  MRI machines only use a magnetic field .  In addition, the PET scan will require that you be injected with an agent that 
contains a radioactive tag so that the wellness of the cel ls in and around your stroke area can 
be evaluated.  
  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  
  
  Page 64 of 85 Surgical Procedure and Administration of the Cells:  
The SB623 cells are to be implanted directly into your brain in and around the area of the 
stroke.  To do this, you will have a small hole drilled int o your skull.  This will be done under 
local anesthesia.  The exact position of the hole to be made will be determined by [CONTACT_418610].  MRI (Magnetic Resonance Imaging) is a special procedure using an instrument with a very strong magne t.  A special apparatus will be used on your head to 
make sure the hole is positioned such that the implantation of the cells will be precisely into the stroke region, at location also determined by [CONTACT_9268].  A needle will be inserted through the hole into your brain extending into and slightly beyond the main stroke region.  Cells will be implanted at 5 sites through this one needle injection.  Two additional needle insertions with 5 more implantation sites each will also be done at slightly different angles.  
There will be 3 groups of patients enrolled in this study.  Your assignment to a particular group by [CONTACT_418611].  Six patients will be studied in group 1 before proceeding to 6 patients in group 2, who in turn will be studied before proceeding to 6 patients in group 3.  The total amount of cells you will receive will depend on which group you are in.  Group 1 patients will receive 2.5 million cells; group 2 patients will receive 5 million cells; and group 3 patients will receive 10 million cells.  All patients will receive a total of 300 µL of fluid (about 1/3
rd of mL, or less than 1/10th of a 
teaspoon or about [ADDRESS_528042] dropper).  
Study Procedures:  
You will be asked to provide blood samples throughout the study in addition to any samples required for your normal care.  Approximately 25 mL (a little less than one ounce or two tablespoons) of blood will be drawn at total of [ADDRESS_528043] scan (a 
type of imaging procedure using a contrast agent and X -rays) to determine that you have no 
compl ications, and then will be admitted to a neurosurgical patient ward for [ADDRESS_528044] -operative day.  
Periodically, you will also receive a PET scan.  PET stands for Positron Emission 
Tomography.  In this pro cedure, a marker similar to glucose (a sugar) containing an atom 
that emits radiation (positron) will be injected into your blood stream.  A machine that measures this radiation will determine if your brain cells are behaving in the usual manner in absorbi ng the glucose marker.  
You will be asked to periodically undergo additional MRI scans to assess your progress  and 
to evaluate safety .  You will also be asked standardized questions about your stroke 
symptoms and be asked to make certain movements as you di d during your screening.  
REQUEST FOR AUTOPSY:  
In the event of your death during the study from any cause, the study doctor will ask your family for permission to perform an autopsy.  The evaluation of organs and tissues after death is a very valuable method to learn more about any effects of the study agent.  You 
should talk about the possibility of an autopsy with your family and health provider, and advise them of your wishes.  The study sponsor will pay all costs of the autopsy.  
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 65 of 85 POSSIBLE RISKS AND DISCOMFORTS:  
This is the first time that SB623 cells have been administered to people, so possible side 
effects are not known, except that mild, post -surgical headache that resolved within [ADDRESS_528045] cohort of subjects..  It has been administered to animals 
(rats and monkeys) with no negative cell -related effects observed.  Since the cells did not 
survive longer than [ADDRESS_528046] scan include rare allergic reactions, nausea, flushing, low blood pressur e, asthma, stroke and organ damage.  The PET scans will 
also expose you to a low level of radiation from the injected radioactive agent (FDG).  
Although animal studies up to [ADDRESS_528047] your willingness to continue participation in the study will be provided to you.  
  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  
  
  Page 66 of 85 If you experience more than minimal discomfort after completing the implantation 
procedure, you should:  
1. Call the study doctor at once at telephone number: (xxx) xxx -xxxx  
2. If necessary, go to the nearest emergency room  
During this study, you will receive the standard care for your condition (including antibiotics, 
pain medicine, cardiovascular support, ventilator support, and hospi[INVESTIGATOR_059]) as required.  
PREGNANCY/ BIRTH CONTROL:  
If you are pregnant or nursing a child, you cannot take part in this study since there is no known information about potential harm to unborn children.  If you are a woman who has had a tubal ligation, hysterectomy, or are post -menopausal, you may be eligible to take part 
in this study.  If you are a w oman of child- bearing potential you must practice acceptable 
methods of birth control (oral, implantable, or injectable contraceptives; spermicide in conjunction with a barrier such as a condom or diaphragm; intrauterine device or IUD) for at least the fir st 6 months of the study.  
ALTERNATIVES TO PARTICIPATION:  
There are no approved therapi[INVESTIGATOR_418553] -related condition.  The study doctor has 
discussed any other options available to you, including non- participation in this study.  If you 
decide not to take part in this study, it will not affect your future treatment.  
POSSIBLE BENEFITS:  
Although it is hoped that participation in this trial may lead to some improvement in your condition, the primary goal of this study is to establish safety of the approach rather than to 
maximize the chance for improvement.  Accordingly, you should not expect to receive benefit from participation in this study.   However, the knowledge obtained from this research 
may help the health care professionals caring for you to better treat other patients undergoing treatment for a condition similar to yours.  
COMPENSATION FOR PARTICIPATION:  
There is no additional cost  to you for participation in this research study beyond the costs 
normally associated with your treatment.  The  SB623 cells will be provided free of charge to 
you by [CONTACT_1034].  The physician visits and associated tests related to the study will also be provided at no cost.  You will be reimbursed any out -of-pocket expenses relating to 
participation in this resea rch study.  
MEDICAL CARE FOR INJURY RELATED TO THIS STUDY:  
In the event of injury resulting from your participation in this research, medical care will be provided to you by [CONTACT_39635].  The care will be free of charge to you.  The Sponsor of the Stud y is insured in the event you are injured through participation in the study.  
CONFIDENTIALITY AND RELEASE OF MEDICAL RECORDS:  
The study doctor will provide information about your treatment to the Sponsor (SanBio Incorporated) and/or its representative.  You have the right to privacy, and all information obtained in this study that can identify you individually will remain confidential to the extent possible within the state and federal laws.  Only your patient number and initials will be 
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 67 of 85 recorded on study documents and reports.  Your name [CONTACT_418623].  Other information, including your gender, age, and 
ethnicity, will be recorded on study documents for the purposes of analyses of the study outcome.  Nothing in the study documents will provide any identification of you.  
Governmental and institutional regulatory authorities and the Sponsor and/or its designee (the site monitor), may inspect and copy your records pertaining to this study.  The re sults of 
the study will be reported to governmental agencies.  
In the rare instances for which regulatory authorities may require patient names, the regulatory authorities will treat such information as confidential, but disclosure to third parties may be r equired on rare occasions.  Therefore, absolute protection of confidentiality 
by [CONTACT_418612]. 
Because this study involves genetically -modified cells, safety information must be reported 
to the Recombinant DNA Advisory Committee of the National Institutes of Health.  This 
information is available to the public.  However, no information by [CONTACT_418613].  We will try to keep your identity and other inf ormation collected in this study confidential.  There may be some exceptions when 
the law requires disclosure.  Representatives of [study site], and/or the Food and Drug Administration, and/or the National Institutes of Health, or other regulatory agencies  outside 
[study site] may ask to review the data collected from this study.  These groups can have access to your name [CONTACT_418624].  
It is possible that the media may want to find out about you because you took part in this study.  We will take ever y precaution to protect your privacy and that of your family.  We 
will also maintain the confidentiality of the research data.  To lower the chance that your identity will be made public, all requests for information will be directed to the [study site] 
Public Relations Office.  Despi[INVESTIGATOR_120502], reporters may try to find out who you are 
without the approval of the [study site].  If the media succeed, they might ask to interview you and your privacy may be invaded.  Every effort will be made to protect  your privacy but 
it may not be possible to do so. 
VOLUNTARY PARTICIPATION AND WITHDRAWAL:  
Your participation in this study is voluntary and you are free to withdraw at anytime.  Any 
new information developed during this research that may be related to your willingness to continue participation will be provided to you.  Participation or withdrawal will involve no penalties or loss of benefits to which you are otherwise entitled, and will not affect your future medical care.  
Your participation in this study may be discontinued without your consent for the following reasons:  
• if treatment appears to be medically harmful to you  
• if you fail to follow directions for participation in the study  
• if it is discovered you do not meet the eligibility requirements  
• if the study is canceled  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.[ADDRESS_528048]:  
The study doctor is a researcher in thi s study.  As a researcher, he is interested not only in our 
health and well being, but also in the results of this study.  It is pos sible that sometimes these 
two goals may conflict with one another.  Researchers protect the rights and interests of 
partici pants by [CONTACT_418614].  
This research is sponsored by [CONTACT_418615], Inc.  This means that SanBio is paying the research team for the costs of doing the study.  The researchers do not have a financial stake in the results of the study . 
  
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 69 of 85 OFFER TO ANSWER QUESTIONS ABOUT THIS STUDY:  
If you have questions about this study, your condition and/or treatment, or if you experience 
a research -related injury or illness, you should contact  [CONTACT_418616], MD at: (xxx) 
xxx-xxxx 
If you have questions about your rights as a research patient, you may contact a representative of the Ethics Committee for this institution at (xxx) xxx- xxxx.   
CONSENT TO PARTICIPATE IN THIS STUDY:  
Your consent to participate in research should be voluntary and informed.  By [CONTACT_3368], you acknowledge that you have read this information (or had it read to you), been given an opportunity to ask questions about the information provided in this form, and understand the potential risks and benefits.  By [CONTACT_2960] t his form you indicate that you wish 
to participate in the study at this time.  
Having consented, you still have the right to withdraw at any time without jeopardy to your care.  If you wish to withdraw, you should notify the study doctor or study coordinator; you do not have to give a reason if you do not wish to.  You will not lose any legal rights as a research patient by [CONTACT_3368].  
You will be given a signed copy of this form to keep and refer to as needed. 
 
   
Signature [CONTACT_418625], Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  
  
  Page 70 of 85 21.0 APPENDIX B:  ESSENTIAL STUDY DOCUMENTS  
 
 
 
DOCUMENT  LOCATION  COLLECTION TIME  
The following documents will be obtained for 
the regulatory files at the indicated times during the trial Sponsor  Site Pre-
Study  During  Post-
Study  
Investigator’s Drug Brochure  X X X   
Signed protocol and amendments, if any  X X X   
Sample Case -Report Form (CRF)  X X X   
Informed -Consent Form  X X X   
Any other written information given to trial 
patients  X X X   
Advertisement for patient recruitment, if used   X X   
Financial aspects of the trial  X X X   
Insurance statement, where required  X X X   
Signed agreement between:  
• Investigator/institution and Sponsor  
• Investigator/institution and CRO, where 
required  
• Sponsor and CRO  
• Investigator/institution and authority(ies), 
where required  X X X   
Dated, documented approval/favorable opi[INVESTIGATOR_418554]/IEC for:  
• Protocol and any amendments  
• CRF, if applicable  
• Informed -Consent Form  
• Any other written information to be provided to the patient(s)  
• Advertisements for patient recruitment, if used 
• Subject compensation, if any  
• Any other documents given 
approval/favorable opi[INVESTIGATOR_1649]  X X X   
IRB/IEC committee composition  X* X X   
Regulatory authority(ies) 
authorization/approval/ notification of protocol, 
where required  X* X* X   
Curriculum vitae and/or other relevant 
documents evidencing qualifications of 
Investigator(s) and Sub-investigators  X X X   
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.[ADDRESS_528049]-
Study  
Normal value(s)/range(s) for 
medical/laboratory/technical procedure(s) 
and/or test(s) included in the protocol  X X X X  
Medical/laboratory, technical procedures/tests  
• Certification or  
• Accreditation or  
• Established quality control and/or external 
quality assessment or  
• Other validation, where required  X X* X   
Sample of label(s) attached to investigational 
product container(s)  X X X   
Instructions for handling of investigational 
product(s) and trial -related materials, if not 
included in the protocol or Investigator’s 
Brochure  X X X   
Shippi[INVESTIGATOR_418555](s) 
and trial -related materials  X X X   
Decoding procedures for blinded trials  X† X X   
Investigator’s Brochure updates  X X  X  
Revisions to:  
• Protocol/amendment(s)  
• CRF(s)  
• Informed Consent Form(s)  
• Any other written information provided to 
patients  
• Advertisements for patient recruitment, if 
used X X  X  
Dated, documented approval/favorable opi[INVESTIGATOR_418554]/IEC for:  
• Protocol amendments  
• Revisions to Informed -Consent Form  
• Revisions to any other written information to be provided to the patient  
• Advertisements for patient recruitment, if used 
• Any other documents given approval/favorable opi[INVESTIGATOR_1649]  
• Continuing review of trial  X X  X  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.[ADDRESS_528050]-
Study  
Regulatory authority(ies) 
authorizations/approval/ notifications for 
protocol amendment(s) and other documents  X X*  X  
Curriculum vitae for new Investigator(s) and/or 
Sub-investigators  X X  X  
Updates to normal value(s)/range(s) for medical 
laboratory/technical procedure(s)/test(s) 
included in the protocol  X X  X  
Updates of medical/laboratory/technical 
procedures/test  
• Certification or  
• Accreditation or  
• Established quality control and/or external 
quality assessment or  
• Other validation, where required  X X*  X  
Documentation of investigational product(s) and 
trial-related materials shipment  X X  X  
Relevant communications other than site visits  
• Letters  
• Meeting notes  
• Notes of telephone calls  X X  X  
Signed Original Informed -Consent Form   X    
Signed Informed -Consent Form --Copy  X   X  
Source documents   X  X  
Signed, dated, and completed CRFs  X‡ X§  X  
Documentation of CRF corrections  X‡ X§  X  
Notification by [CONTACT_418617]  X X  X  
Notification by [CONTACT_166327]/or Investigator, 
where applicable, to regulatory authority(ies) 
and IRB(s)/IEC(s) of unexpected serious adverse drug reactions and of other safety 
information  X X*  X  
Notification by [CONTACT_418618]  X X  X  
Interim or annual reports to IRB/IEC and 
authority(ies)  X* X  X  
Subject screening log  X* X  X  
Subject identification code list   X  X  
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.[ADDRESS_528051](s) accountability at the 
site X X  X X 
Record of retained body fluids/tissue samples, if 
any X X  X X 
Documentation of investigational product(s) 
destruction  X X║  X X 
Completed patient identification code list   X   X 
Final report by [CONTACT_10670]/institution to 
IRB/IEC where required, and where applicable, 
to the regulatory authority(ies)  X X   X 
Clinical study report  X X¶   X 
 *  Where required  
†  Third party if applicable  
‡  Original   § Copy  
║ If destroyed at site  
¶  If applicable  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  
  
  Page 74 of 85 22.0 APPENDIX C: WHO STANDARD TOXICITY CRITERIA  
The WHO Standard Toxicity Criteria is tabulated below in Table 6.  
Copi[INVESTIGATOR_418556]. 
 For abnormalities not found elsewhere in the WHO table, use the following scale to assign grade or severity:  
  
Grade 1  Mild  Transient of mild discomfort; no limitation in 
activity; no medical intervention/therapy require d. 
Grade 2  Moderate  Mild -to-moderate limitation in activity; some 
assistance may be need.  No or minimal medial 
intervention/therapy required.  
Grade 3  Severe  Marked limitation in activity, some assistance 
usually required; medical intervention/therapy required; hospi[INVESTIGATOR_85153].  
Grade 4  Life-threatening  Extreme limitation in activity, significant 
assistance required; significant medial intervention/therapy required; hospi[INVESTIGATOR_418557].  
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14      Page 75 of 85 Table 6 WHO (World Health Organization) Toxicity Criteria by [CONTACT_418619] 0  Grade 1  Grade 2  Grade 3  Grade 4  
Haematology  WBC (x103/l)  4  3.0 - 3.9  2.0 - 2.9  1.0 - 1.9  < 1.0  
Haematology  Platelets (x103/l)  WNL  75.0 - normal  50.0 - 74.9  25.0 - 49.9  < 25.0  
Haematology  Haemoglobin 
(g/dl)  WNL  10.0 -  normal  8.0 - 9.9  6.5 - 7.9  < 6.5  
Haematology  Granulocytes/ 
Bands (x103/l)  2  1.5 - 1.9  1.0 - 1.4  0.5 - 0.9  < 0.5  
Haematology  Lymphocytes 
(x103/l)  2  1.5 - 1.9  1.0 - 1.4  0.5 - 0.9  < 0.5  
Haematology  Haemorrhage  none  mild, no  gross, 1 - 2 units 
transfusion per 
epi[INVESTIGATOR_418558], 3 - 4 units 
transfusion per 
epi[INVESTIGATOR_418559], > 4 units 
transfusion per epi[INVESTIGATOR_418560]  0.99 - 0.75 x N  0.74 - 0.50 x N  0.49 - 0.25 x N  < 0.25 x N  
Coagulation  Prothrombin 
time(Quick)  WNL  1.01 -  1.25 x N  1.26 - 1.50 x N  1.51 - 2.00 x N  > 2.00 x N  
Coagulation  Partial 
thromboplastin 
time  WNL  1.01 -  1.66 x N  1.67 - 2.33 x N  2.34 - 3.00 x N  > 3.00 x N  
Metabolic  Hyperglycaemia 
(mg/dl)  < 116  116 -  160  161 - 250  251 - 500  > 500 or ketoacidosis  
Metabolic  Hypoglycaemia 
(mg/dl)  > 64  55 - 64  40 - 54  30 - 39  < 30  
Metabolic  Amylase  WNL  < 1.5 x N  1.5 - 2.0 x N  2.1 - 5.0 N  > 5.0 x N  
Metabolic  Hypercalcaemia 
(mg/dl)  < 10.6  10.6 -  11.5  11.6 - 12.5  12.6 - 13.4  13.5  
Metabolic  Hypocalcaemia 
(mg/dl)  > 8.4  8.4 - 7.8  7.7 - 7.0  6.9 - 6.1  6  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14      Page 76 of 85 Category  Toxicity  Grade 0  Grade 1  Grade 2  Grade 3  Grade 4  
Metabolic  Hypomagnesaemia 
(mg/dl)  > 1.4  1.4 - 1.2  1.1 - 0.9  0.8 - 0.6  0.5  
Gastrointestinal  Nausea  none  able to eat 
reasonable intake  intake significantly 
decreased but can eat  no significant 
intake  __  
Gastrointestinal  Vomiting  none  1 epi[INVESTIGATOR_85712] 24 hrs  2 - 5 epi[INVESTIGATOR_11630] 24 
hrs  6 - 10 epi[INVESTIGATOR_11630] 
24 hrs  > 10 epi[INVESTIGATOR_11630] 24 hrs 
or requiring parenteral 
support  
Gastrointestinal  Diarrhoea  none  increase of 2 -  3 
stools / day over 
pre-Rx  increase of 4 - 6 
stools / day, or 
nocturnal stools, or 
moderate crampi[INVESTIGATOR_418561] 7 - 9 
stools / day, or 
incontinence, or 
severe crampi[INVESTIGATOR_418561] > 10 stools / 
day or grossly bloody diarrhoea, or need for 
parenteral support  
Gastrointestinal  Stomatitis  none  painless ulcers, erythema, or mild soreness  painful erythema, 
oedema, or ulcers but 
can eat solids  painful erythema, 
oedema, or ulcers 
and cannot eat 
solids  requires parenteral or enteral support for alimentation  
Liver  Bilirubin (N = 17 
µmol/L)  WNL  -----  < 1.5 x N  1.5 - 3.0 x N  > 3.0 x N  
Liver  Transaminase 
(SGOT, SGPT)  WNL  2.5 x N  2.6 - 5.0 x N  5.1 - 20.0 x N  > 20.0 x N  
Liver  Alk Phos or 5 
nucleotidase  WNL  < 2.5 x N  2.6 - 5.0 x N  5.1 - 20.0 x N  > 20.0 x N  
Liver  Liver - clinical  No change 
from baseline  -----  -----  precoma  hepatic coma  
Kidney, bladder  Creatinine  WNL  < 1.5 x N  1.5 - 3.0 x N  3.1 - 6.0 x N  > 6.0 x N  
Kidney, bladder  Proteinuria  No change  1 (+) or < 0.3 g% 
or 3 g/L  2 - 3 (+) or 0.3 - 1.0 
g% or 3 - 10 g/L  4 (+) or > 1.0 g% 
or > 10g/L  nephrotic  syndrome  
Kidney, bladder  Haematuria  Negative  microscopic only  gross, no clots no Rx 
needed  gross and clots 
bladder irrigation  requires transfusion or 
cystectomy  
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14      Page 77 of 85 Category  Toxicity  Grade 0  Grade 1  Grade 2  Grade 3  Grade 4  
Kidney, bladder  Weight gain/ loss  < 5.0 %  5.0 - 9.9 %  10.0 - 19.9 %  20.00%  -----  
Pulmonary  Pulmonary  none or no 
change  asymptomatic, with 
abnormality in 
PFTs  dyspnoea on 
significant exertion  dyspnoea at 
normal level of 
activity  dyspnoea at rest  
Cardiac  Cardiac 
arrhythmias  none  asymptomatic, transient, requiring no therapy  recurrent or 
persistent, no therapy 
required  requires 
treatment  requires monitoring; or 
hypotension, or ventricular tachycardia 
or fibrillation  
Cardiac  Cardiac function  none  asymptomatic, 
decline of resting ejection fraction by [CONTACT_21316] 20 % of 
baseline value  asymptomatic, 
decline of resting 
ejection fraction by 
[CONTACT_726] 20 % of 
baseline value  mild CHF, 
responsive to 
therapy  severe of refractory CHF  
Cardiac  Cardiac isc haemia  none  non-specific T - 
wave flattening  asymptomatic, ST 
and T wave changes 
suggesting ischaemia  angina without 
evidence of 
infraction  acute myocardial infarction  
Cardiac  Cardiac - 
pericardial  none  asymptomatic 
effusion, no intervention 
required  pericarditis (rub, 
chest pain, ECG 
changes)  symptomatic 
effusion; 
drainage required  tamponade; drainage urgently required  
Cardiac  Hypertension  none or no change  asymptomatic , 
transient increase by [CONTACT_7809] 20 mm Hg (D) or to > 150 / 100 if 
previously WNL. 
No treatment 
required.  recurrent or 
persistent increase by 
[CONTACT_7809] 20 mm 
HG (D) or to > 150 / 
100 if previously 
WNL. No treatment 
required.  requires therapy  hype rtensive crisis  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14      Page 78 of 85 Category  Toxicity  Grade 0  Grade 1  Grade 2  Grade 3  Grade 4  
Cardiac  Hypotension  none or no 
change  changes requiring no therapy 
(including transient 
orthostatic hypo-tension)  requires fluid 
replacement or other 
therapy but not 
hospi[INVESTIGATOR_418562] ; 
resolves within 
48 hours of 
stoppi[INVESTIGATOR_418563] > 48 hrs after stoppi[INVESTIGATOR_418564]: sensory  none or no change  mild paraesthesias; 
loss of deep tendon 
reflexes  mild or moderate 
objective sensory 
loss moderate 
paraesthesias  severe objective 
sensory loss or 
paraesthesias that 
interfere with 
function  -----  
Neurologic  Neuro: motor  none or no change  subjective weakness; no objective findings  mild objective 
weakness without 
significant 
impairment of 
function  objective 
weakness with 
impairment of 
function  paralysis  
Neurologic  Neuro: cortical  none  mild somnolence or 
agitation  moderate 
somnolence or 
agitation  severe 
somnolence, (> 50 
% waking hours), 
agitation, 
confusion, 
disorientation or 
hallucinations  coma, seizures, toxic psychosis  
Neurologic  Neuro: cerebellar  none  slight 
incoordination, 
dysdiadochokinesia  intention tremor, 
dysmetria, slurred 
speech, nystagmus  locomotor ataxia  cerebellar necrosis  
Neurologic  Neuro: mood  no change  mild anxiety or 
depression  moderate anxiety or 
depression  severe anxiety or 
depression  suicidal ideation  
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14      Page 79 of 85 Category  Toxicity  Grade 0  Grade 1  Grade 2  Grade 3  Grade 4  
Neurologic  Neuro: headache  none  mild  moderate or severe 
but transient  unrelenting and 
severe  -----  
Neurologic  Neuro: 
constipation  none or no 
change  mild  moderate  severe  ileus > 96 hrs  
Neurologic  Neuro: hearing  none or no 
change  asymptomatic, hearing loss on audiometry only  
tinnitus  hearing loss 
interfering with 
function but 
correctable with 
hearing aid  deafness not correctable  
Neurologic  Neuro: vision  none or no change  -----  
-----  symptomatic 
subtotal loss of 
vision  blindness  
Pain  Pain  none  mild  moderate  severe  reg. narcotics  
Skin  Skin  none or no change  scattered macular or papular eruption or erythema that is asymptomatic  scattered macular or 
papular eruption or 
erythema with 
pruritus or other 
associated symptoms  generalised 
symptomatic 
macular, papular 
or vesicular 
eruption  exfoliative dermatitis or 
ulcerating dermatitis  
Alopecia  Alopecia  no loss  mild hair loss  pronounced or total 
hair loss  -----  -----  
Allergy  Allergy  none  transient rash, drug fever < 38
o C 
(100.4o F)  urticaria, drug fever 
38o C (100.4o F), 
mild bronchospasm  serum sickness, 
bronchospasm 
requiring 
parenteral 
medication  anaphylaxis  
Local  Local  none  pain  pain and swelling 
with inflammation or 
phlebitis  ulceration  plastic surgery indicated  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14      Page 80 of 85 Category  Toxicity  Grade 0  Grade 1  Grade 2  Grade 3  Grade 4  
Fever of 
unknown origin  Fever of unknown 
origin  none  37.1 -  38.0o C 
98.7o -  100.4o F  38.1 - 40.0o C 100.5 -  
104o F  > 40.0o C > 
104.0o F for less 
than 24 hrs  > 40.0o C (>104o F) for 
more than 24 hrs or 
accompanied by 
[CONTACT_418620]-threatening  
Additional events  Asthenia  Analogous to 
Karnofsky index (WHO 
grading)              
Additional 
events  Chills  Analogous to 
fever              
Additional 
events  Peripheral oedema  analogous to 
weight gain              
Additional 
events  Anorexia  analogous to 
weight loss              
 
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 81 of 85 23.0 APPENDIX D: COGNITIVE FUNCTION TEST BATTERY  
Table [ADDRESS_528052] Battery  
Estimated Intelligence  
 *Wechsler Abbreviated Scale of Intelligence (WASI) [ADDRESS_528053] Association Category  
 Vocabulary (WASI)  
Attention  
 Trails A Time  
 Digit Vigilance  Accuracy  
Learning and Memory  
 Rey Auditory Learning Test  
 Rey Complex Figure – immediate & delayed recall  
 Logical Memory – WMS -III 
Working Memory  
 Trails B Time and E rrors  
 Letter -Number Sequencing - WMS -III 
Visuospatial/Constructional Ability  
 Rey Complex Figure Copy  
 Matrix Reasoning —WASI  
Psychomotor Efficiency  
 Digit Vigilance Time  
 Trails A Errors  
 Digit Symbol Substitution Test -WAIS -III 
 Grooved Pegboard  
Executive Function (reasoning, mental manipulation)  
 Stroop  Interference  
 Controlled Oral Word Association —FAS 
Mood State and Quality of Life  
 Beck Depression Inventory, 2nd Ed. 
 Beck Anxiety Inventory  
 
 * Baseline only  
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  
  
  Page 82 of 85 24.0 REFERENCES  
                                                 
1  Douketis JD, Spyropoulos AC , et al . Perioperative Management of Antithrombotic 
Therapy: Antithro mbotic Therapy and Prevention of Thrombosis, 9th Edition: American 
College of Chest Physici ans Evidence -Based Clinical Practice Guidelines . Chest. 
2012:141; e326S -e350S. 
2  Warlow C, Sudlow C, Dennis M, Wardlow J, and Sandercock P. Stroke. Lancet. 2003;  
362:1211–1224. 
3  Naidech AM and Weisberg LA, Treatment of chronic hypertension for the preve ntion of 
stroke, South Med J  96 (2003) (4), pp. 359–362  
4  Ingall TJ, Preventing ischemic stroke current approaches to primary and secondary 
prevention, Postgrad Med 107 (2000) (6), pp. 34– 50 
5  Caplan LR, Now is an exciting time to care for stroke patient s, South Med J  2003; 
96:329–330. 
6  American Heart Association, Heart disease and stroke statistics 2007 update. Circ.  2007; 
e99. 
7  Broderick J, Brott T, Kothari R, et al. , The Greater Cincinnati/Northern Kentucky Stroke 
Study preliminary first- ever and total incidence rates of stroke among blacks, Stroke  29 
(1998), pp. 415–421.  
8  Leary MC and Saver JL. Incidence of silent stroke in the [LOCATION_002]  (2001) Poster 
presented at the 26th American Heart Association Stroke Meeting, February, Fort Lauderdale, Fla..  
9  Zweifler RM. Management of Acute Stroke, South Med J  96 (2003) (4), pp. 380–385. 
10  American Heart Association, Heart Disease and Stroke Statistics —2007 Update. 
Circulation. 2007; 115:e69- e171.  
11  Kissela B and Air E. Diabetes: Impact on Stroke Risk and Poststroke Recovery. Sem in Neurol. 2006; 26:100- 107. 
12  Feigin VL, Lawes CMM, Bennett DA, and Anderson CA. Stroke epi[INVESTIGATOR_623] a review of population- based studies of incidence, prevalence, and case -fatality in the late 20th 
century, Lancet Neurol  2 (2003), pp. 43–53.  
13  Toole JF, Sane DC, and Betterman K. Stroke prevention optimizing the response to a common threat, JAMA  292 (2004) (15), pp. 1885 –1887 
14  Bakker K, R auwerda JA, Schaper NC. Diabetes Metab Res Rev.  2000; 16 (Suppl 1): S1  
15  Smith WS, Hauser SL, Easton JD. Cerebrovascular Diseases. In: Braunwald E, Hauser S, Fauci AS, Longo DL, Kasper DL, Jameson JL, editors. Harrison’s Principles of Internal Medicine. 1 5
th ed. [LOCATION_001]: McGraw -Hill; 2001. 
16  Engelstein E, Margulies J, and Jeret JS. Lack of t -PA use for acute ischemic stroke in a 
community hospi[INVESTIGATOR_418565], Am J Emerg Med  18 (2000), pp. 
257–260 
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR01 Amendment 5.0 11- Sep-14  Page 83 of 85                                                                                                                                                        
17  Kreisel SH, Hennerici MG, and  Bäzner H. Pathophysiology of Stroke Rehabilitation: The 
Natural Course of Clinical Recovery, Use- Dependent Plasticity and Rehabilitative 
Outcome. Cerbrovasc Dis . 2007; 23:243- 255. 
18  Duncan PW, et al . Measure of Motor Recovery after Stroke. Outcome Assessment and 
Sample Size Requirements. Stroke.  1992; 23:1084- 1089. 
19  Hendricks HT, et al. Arch Phys Med Rehabil . 2002; 83:1629- 1637. 
20  Jergensen HS, et al. Outcome and Time Course of Recovery in Stroke. Part II: Time 
Course of Recovery. The Copenhagen Stroke Study. Arch Phys Med Rehabil . 1995; 
76:408- 412. 
21  Bliss T, Guzman R, Daadi M, Steinberg GK. Cell Transplantation Therapy for Stroke. 
Stroke . 2007; 38(part 2:817- 826. 
22  Kondziolka D, Wechsler L, Achim C. Neural Transplantation for Stroke. J Clin Ne urosci . 
2002; 9:225- 230. 
23  Savitz SI, Dinsmore JH, et al . Cell Therapy for Stroke. NeuroRx . 2004; 1:406- 414. 
[ADDRESS_528054] Growth Patterns of Glial and Axonal Fibres. Nat Med . 1998; 1:1189- 1194 
25  Deacon TW, Pakzaban P, et al.  Cytoarchitectonic Development, Axon- Glia Relationships, 
and Long Distance Axon Growth of Porcine Striatal Xenografts in Rats. Exp.  Neu rol. 
1994; 130:151- 167. 
26  Dinsmore JH, Martin J, et al . CNS Grafts for Treatment of Neurologic Disorders. In: 
Methods of Tissue Engineering, Ed 1 pp 1127- 1134. San Diego: Academic Press, 2002. 
27  Borlongan CV, et al. Transplantation of Cryopreserved Human Embryonal Carcinoma -
Derived Neurons (NT2N Cells) Promotes Functional Recovery in Ischemic Rats. Exp Neurol. 1998; 149:310- 321. 
28  Kondziolka D, Wechsler L, et al.  Transplantation of Cultured Human Neuronal Cells for  
Patients with Stroke. Neurobiol. 2000; 55:565- 569. 
29  Kondziolka D, Steinberg GK, Wechsler L, et al. Neurotransplantation for Patients with 
Subcortical Motor Stroke: A Phase 2 Randomized Trial. J Neurosurg. 2005; 103:38- 45. 
[ADDRESS_528055] Neurosurg. 2008; 
86:278- 287. 
31  Hantson L, DeWeerdt W, et al. The European Stroke Scale. Stroke . 1994; 25:2215- 2219. 
32  Brott T, Adams HP, et al . Measurements of Acute Cerebral Infarction: a Clinical 
Examination Scale. Stroke.  1989; 20:864- 870. 
33  Goldstein LB, Bertels C, Davis JN. Interrater Reliability of the NIH Stroke Scale. Arch Neurol. 1989; 46:660- 662. 
 
SanBio, Inc   Confide ntial and Proprietary  
 
Protocol SB -STR01 Amendment 5.0 11- Sep-14  
  
  Page 84 of 85                                                                                                                                                        
34  Rankin J. Cerebral V ascular Accidents in patients over the Age of 60. Scott Med J . 1957; 
2:200- 215. 
35  Bonita R and Beaglehole R. Recovery of Motor Function after Stroke. Stroke. 1988; 
19:1797- 1500. 
36  Adams RJ, Meador KJ, et al.  Graded Neurologic Scale for User in Acute Hemi spheric 
Stroke Treatment Protocols. Stroke . 1987; 18:665- 669. 
[ADDRESS_528056] -Stroke Hemiplegic 
Patient. 1. A Method for Evaluation of Physical Performance. Scand J Rehabil Med. 1975; 7:13- 31. 
[ADDRESS_528057] PW, Gowland C. Reliability of the Fugl -
Meyer Assessment for Testing Motor Performance in Patients Following Stroke. Phys Ther . 1993; 73:447- 454. 
39  Stilley CS, Ryan CM, Kondziolka D, Bender A, DeCesare S, Wechsler L. Changes in Cognitive Function after Neuronal Cell Transplantation for Basal Ganglia Stroke. Neurol . 
2004; 63:1320- 1322. 
[ADDRESS_528058] . 
2004; 113:1701- 1710. 
[ADDRESS_528059] romal cells and 
their derivative, SB623 cells, rescue neural cells via trophic support following in vitro ischemia . Cell Transplantation. 2010: DOI: 10.3727/096368910X494885. 
44  Aizman I, Tate CC, McGrogan MM, and Case CC. Extracellular Matrix Produced by [CONTACT_418621] t heir Derivative, SB623 Cells, Supports Neural  Cell 
Growth . J Neurosci Res . 2009; 87:3198- 3206. 
45  Bohn M. Northwestern University. 2007. Unpublished data.  
46  Study conducted for SanBio by [CONTACT_418622]. 
47  Paxinos G, Watson C.  The Rat Brain in Stereotaxic Coordinates . 4th ed.  San Diego: 
Academic Press; 1998.  
48  Study Number 1295- 001. Implantation of SanBio Cells into the Brains of Athymic Nude 
Rats: A Short -term Biodistribution Study. MPI [INVESTIGATOR_133720], 2007.  
49  Study Number 1295- 002. Implantation of SanBio SB623 Cells into the Brains of Male 
and Female Athymic Nude Rats: A Tumorigenicity Study. MPI [INVESTIGATOR_133720], 2007. 
50  Study Number 1295- 008: Implantation of SanBio SB623 Cells into the Brains of Male 
and F emale Athymic Nude Rats. MPI [INVESTIGATOR_133720] 2008. Study in progress.  
[ADDRESS_528060] . 
2004; 13:749- 754. 
55  http://www.elekta.com/healthcare_us_leksell_stereotactic_system.php  
56  Spi[INVESTIGATOR_84620] J, et al . J Neurosci Nurs. 1997; 29:384- 392. 